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The ocular surface is continually exposed to the outside environment and is a
common site of inflammation. Conjunctival epithelial cells are thought to play a role
in innate responses at the ocular surface. The hypothesis of my study is that
conjunctival epithelial cells also contribute to T cell and mast cell effector
mechanisms in chronic allergic eye disease via secretion of cytokines. In this study
we initially demonstrate that the conjunctiva expresses TLRs, and that the TLR3
ligand (poly I:C) activates conjunctival epithelial cells in vitro to secrete
inflammatory mediators as part of the innate immune response. Conjunctival tissues
were also shown to express the Th2 associated cytokine, IL-13 as well as TSLP – a
cytokine thought to be involved in Th2 differentiation. Conjunctival tissues from
chronic allergic eye disease subjects were found to have increased IL-13 and TSLP
expression compared to normal controls. Using a human conjunctival epithelial cell
line, cells could be induced to express increased levels of TSLP following exposure
to poly I:C or pro-inflammatory cytokines. Th17 cells, identified by coexpression of
CD4 and IL-17, were also detected in CAED tissues and a high level of expression of
IL-17A was localised to the epithelium. However, although capable of secreting IL-
25, IL-17A was not secreted by conjunctival epithelial cells, indicating that the IL-17
observed histologically may have been IL-17 binding to the surface of the
epithelium. IL-17 receptor C (IL-17RC) expression was found to be increased in
CAED tissues whilst IL-17RA was upregulated when conjunctival epithelial cells
were stimulated with pro-inflammatory cytokines together with poly I:C. Blockade
of IL-17RA and subsequent stimulation with IL-17 led to increased IL-8 and
decreased TGF-β secretion. Although being implicated in the immunopathogenesis 
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of certain diseases, IL-17 and its other family members may potentially serve to play
an immunoregulatory role in immunity at the ocular surface.
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1.1 The mucosal immune system
The mucous membranes which in addition to the conjunctiva cover other areas such
as the respiratory, digestive and urogenital tract, have a highly specialised immune
system which becomes activated in response to direct destruction or invasion of
pathogens through the epithelial surface. The cells that form part of this local
immune system are accumulated in or are in transit between mucosal organs and
glands that form the mucosa-associated lymphoid tissues (MALT), a secondary
lymphoid organ. The main functions served by the MALT are to protect the mucous
membranes from colonisation and invasion by dangerous microbes, to prevent the
uptake of non-degraded antigens and prevent the development of harmful immune
responses to these antigens if they make their way through (Lugton, 1999). Within
the MALT there are a number of cells that actively participate towards the immune
response, some of which play a regulatory role. These cells include B lymphocytes,
T helper (Th) and regulatory T cells (Tregs). There are also a number of accessory
cells such as immature dendritic cells (iDCs) and macrophages involved in
phagocytosis and presentation of antigen to T lymphocytes.
1.2 Innate immunity
The innate immune response has evolved as a first line of defence; its actions are
immediate but non-specific and rapidly eliminate or diminish invading pathogens.
Many different components make up the innate immune system; these can take the
form of physical barriers to pathogen invasion such as the skin and mucous
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membranes and also cellular and serum factors activated by secreted or cell surface
products of the pathogen. These factors also induce an inflammatory response that
leads to secretion of inflammatory cytokines and chemokines, which in turn leads to
the recruitment of other cells regarded as part of the innate immunity.
1.2.1 Polymorphonuclear leukocytes
Some of the cells forming the innate immune system are termed polymorphonuclear
leukocytes (PMNs) or granulocytes because of the granules stored within. There are
three types, the most abundant being neutrophils which are characterised by their
lobed nuclei and make up about 90% of circulating granulocytes and 65-75% of
white blood cells in peripheral circulation. These are phagocytic cells that specialise
in ingesting, killing and degrading phagocytosed microbes, and are the predominant
cells in acute inflammatory infiltrates; once an inflammatory response is initiated,
neutrophils are the first cells to be recruited to sites of infection or injury. The targets
of this cell include bacteria, fungi, protozoa, viruses, virally infected cells and
tumour cells (Smith, 1994). The other two forms of circulating granulocytes are
eosinophils which account for 2-5% of white cells in the blood and basophils which
make up less than 1%. Tissue mast cells are also included here as they are a close
relative of basophils. These cells are important in the host defence to multicellular
pathogens, in particular to helminths. Unlike neutrophils that phagocytose, the
defensive function of these cells is due to their ability to discharge potent biological
mediators into the cellular microenvironment, a process known as degranulation.
Degranulation can be triggered by antigen-specific IgE molecules bound to basophils
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and mast cells which express high affinity receptors for the Fc portion of IgE
(FcεRI). Other cells considered part of the innate immune system are 
monocytes/macrophages, natural killer cells (NK cells) and dendritic cells (DCs),
which can also be phagocytic but, unlike PMNs, they do not contain granules.
Instead, they contain lysosomes within the cytoplasm that can secrete pre-formed
proteins such as perforin and a family of serine proteases called granzymes (Chertov
et al, 2000).
1.2.2 Mast cells
Mast cells are mainly found in the mucosal and connective tissues of the skin, lung
and gut and, as previously described, have cytoplasmic granules containing heparin,
histamine and proteases, which upon activation can be released into the tissues
(Klaus et al, 1996). Although mast cells have a key role in immediate type I
hypersensitivity responses, the early phase, it is also thought that mast cells take part
in the late phase of an immune response or as part of the memory response. The
binding of IgE to mast cell Fc receptors leads to their activation, but they can also be
activated directly by pathogens or even microbial products via toll-like receptors
(TLRs) or cytokines (Galli et al, 2005). Following activation, these cells do not only
release preformed mediators, they can also secrete a variety of cytokines,
chemokines and growth factors including interleukin-10 (IL-10) and TGF-β, which 
not only orchestrate the inflammatory response but underline a potential suppressive
action of these cells (Galli et al, 2005). Mast cells are key cells in providing host
resistance to parasites, as demonstrated in mice deficient in IgE, but they have also
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been associated with the development of airway hyperresponsiveness in a mouse
model of asthma (King et al, 1997; Kobayashi et al, 2000).
1.2.3 Epithelial cells
The cellular components of the innate immune system described earlier, are not the
only innate cells capable of providing host defence to pathogens. Epithelial cells line
the areas of the body such as the respiratory tract, intestines, skin and the ocular
surface. These cells provide an interface between the internal and external
environment and are the first point of contact to microorganisms, airborne allergens
and environmental pollutants (Diamond et al, 2000).
The role of the epithelium in innate immunity is of great importance, considering that
failure in their mechanism may result in microbial colonisation and subsequent
infection. The mechanisms by which epithelial cells recognise pathogens is through
pattern recognition receptors / molecules present in secretions such as mannan-
binding lectin, or as transmembrane molecules like TLRs (see section 1.2.4.1) (Bals
& Hiemstra, 2004). Upon recognition of a pathogen, epithelial cells respond by
releasing antimicrobial peptides as well as cytokines and chemokines (refer to
section 1.2.4). Secretion of these mediators allows the epithelium to chemoattract
and activate innate and adaptive immune cells, immobilise and kill microorganisms
and orchestrate the initiation of an adaptive immune response. In response to injury,
epithelial cells can also induce wound healing and angiogenesis (Allan et al, 2008).
In regards to the antimicrobial peptides, many groups have investigated the
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expression and production of defensins and cathelicidin (LL-37) in the mucosa. In
host defence, both types of peptides have two major functions; direct inhibition of
pathogens and modulation of other innate and adaptive immune functions (Doss et
al, 2010).
Within the epithelium, enterocytes and goblet cells produce mucin glycoproteins
providing a barrier and thereby limiting the access of the microbiota to the apical
side of the lumen (Rescigno, 2011). It has recently been shown that an increase in the
production of the mucin Muc2, in mice infected with Trichuris muris, correlated with
worm expulsion. However, mice deficient in Muc2 experienced delayed worm
expulsion 20 days after infection, indicating the importance of mucins in innate
defence and enteric infection (Hasnain et al, 2010). Such observations have further
added to the opinion that epithelial cells not only provide a barrier function, but
actively participate in the innate immune response.
1.2.4 Pattern recognition receptors
Although the innate immune system is regarded as relatively nonspecific, it still has
the ability to discriminate between what is self and what is foreign, for example with
defence to viruses. To carry out this role, the innate immune system relies on pattern
recognition receptors (PRRs). These receptors can be secreted or expressed on cell
surfaces and in intracellular compartments, in which their principal functions include
opsonization, activation of complement and coagulation cascades, phagocytosis,
activation of pro-inflammatory signalling pathways, and induction of apoptosis
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(Janeway & Medzhitov, 2002). These receptors can be activated by interaction with
specific molecular structural motifs on pathogens, called pathogen-associated
molecular patterns [PAMPs] (Vroling et al, 2008). The best studied group of PRRs
are the TLRs, so-called as they are the mammalian homolog of the Drosophila Toll
receptor, responsible for this organism’s activation of host-defence mechanisms in
response to infection (Lemaitre et al, 1996).
1.2.4.1 TLRs
To date, 10 functional TLRs have been identified in humans and their expression has
been found to have a very broad distribution. Innate immune cells such as PMNs,
mast cells, NK cells and DCs express most classes of TLRs. This expression also
extends to T and B cells as well as endothelial cells, epithelial cells, skin
keratinocytes and fibroblasts (Table 1-1; Chang, 2010). The array of ligands that
bind TLRs are diverse, and includes components of bacterial cell wall, bacterial
genome DNA, viral, fungal and parasitic products and, as such, these receptors fall
into two groups. The first group recognise PAMPs on extracellular pathogens; these
TLRs are expressed on the cell surface and include TLR1, TLR2, TLR4, TLR5 and
TLR6. Conversely, the second group of TLRs are found on the surfaces of
endosomes (TLR3, TLR7, TLR8 and TLR9; Figure 1-1), in which they bind the
nuclear acid of PAMPs from viruses and bacteria (Ishii & Akira, 2008).
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1.2.4.2 TLR signalling
All TLRs belong to the type I transmembrane glycoprotein receptor family which are
characterised by extracellular domains that contain varying numbers of leucine-rich
repeat (LRR) motifs. Additionally, these receptors have a signal transmembrane α-
helix portion and a conserved intracellular domain, homologous to the human
interleukin-1 receptor (IL-1R) and IL-18R which is called the Toll/IL-1R (TIR)
homology domain (Beutler et al, 2006). Upon recognition of their ligands, TLRs
induce the expression of various host defence genes. As well as initiating the
secretion of inflammatory cytokines and chemokines, TLR signalling can induce
production of antimicrobial peptides, expression of costimulatory molecules and
MHC molecules that are necessary in the host defence against invading pathogens.
Engagement of ligands to their respective TLR leads to the recruitment of various
TIR domain containing adaptors, namely MyD88, TIRAP, TRIF and TRAM. Of the
TLRs, TLR1-9, excluding that of TLR3 recruits MyD88 (the MyD88 dependent
pathway). In some instances, namely involving TLR1, TLR2, TLR4 and TLR6,
TIRAP is also recruited which serves as a link between the TIR domain and MyD88.
In contrast to the majority of TLRs, TLR3 initiates the TRIF dependent pathway.
TLR4 can also utilise this pathway via the TIR-containing adaptor TRAM (Figure 1-
1). The activation of NFκB may occur by means of two pathways involving the N-
terminal domain or C-terminal domain of TRIF. In each of these cases, the
recruitment of these adaptors triggers a cascade in the signalling pathway, leading to
the activation of the transcription factor NFκB as well as MAP kinases and 
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subsequent induction in the transcription of inflammatory cytokines, type I
interferons and chemokines (Kumar et al, 2009).
1.2.4.3 TLRs and the immune response
TLRs play a crucial role in the initiation of innate and adaptive immune responses; as
such it does not come as a surprise that they may also be involved in the
pathogenesis of a number of chronic inflammatory diseases. To begin with, these
receptors have demonstrated a protective role in the intestines in response to
commensal bacteria as the ligation of their products to TLRs has been shown to
result in the production of protective factors such as TGF-β and defensins (Ospelt & 
Gay, 2010). Inflammatory or autoimmune diseases could be the result of an
inappropriate response which may be due to a particular genetic background or the
quantity or quality of ligands. In type 1 diabetes mellitus, polymorphisms in TLR2
and TLR3 have been associated with the development of this disease (Park et al,
2004; Pirie et al, 2005). Furthermore in studies using pancreatic islet β cells isolated 
from rats and mice, activation of TLR3 on these cells by dsRNA resulted in their
apoptosis, which is significant owing to the fact that the destruction of β cells is 
characteristic of type 1 diabetes (Dogusan et al, 2008). In other diseases such as
rheumatoid arthritis (RA), the synovium of these patients have been assessed for
their expression of TLRs where it was found that TLR2, TLR3, TLR4 and TLR7 are
upregulated (Radstake et al, 2004; Roelofs et al, 2005; Pierer et al, 2004). Activation
of TLRs can upregulate inflammatory mediators as shown by the increased
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production of TNF-α and IL-6 following stimulation of RA derived DCs with ligands 
for TLR2 and TLR4 (Roelofs et al, 2005).
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Table 1-1 The expression of TLR1-10 on a variety of cell types and the ligands
which bind them (Chang, 2010)
TLRs Major cell types Recognised ligands
TLR1
Myeloid cells, T and B cells, NK
cells, endothelial cells, epithelial
cells, keratinocytes
Forms heterodimers with TLR2 for
bacterial tri-acyl lipopeptide, OSP of
Borrelia spp., and other ligands
TLR2
Myeloid cells, T cells, B cells,
endothelial cells, epithelial cells,
keratinocytes
Peptidoglycan from Gram-positive
bacteria, Mycoplasma lipopeptide,
LPS of leptospirosis and other
spirochetes
TLR3
Myeloid cells, T cells, NK cells,
endothelial cells, epithelial cells,
keratinocytes, neurons
Single-stranded viral RNA (ssRNA)
and double-strand-RNA (dsRNA)
TLR4
Myeloid cells, NK cells, mast cells,
T cells, endothelial cells, epithelial
cells, keratinocytes
BCG, LPS, lipoteichoic acid,
respiratory syncytial virus,
fibronectin, heparin sulfate, fusion
protein
TLR5
Myeloid cells, T cells, NK cells,
endothelial cells, epithelial cells,
keratinocytes
Flagellin from Gram-positive or
Gram-negative bacteria
TLR6
Myeloid cells, T cells, B cells,
endothelial cells, epithelial cells,
keratinocytes
Forms heterodimers with TLR2 for
Mycoplasma di-acyl-lipopeptides, a
peptidoglycan from Gram-positive
bacteria and Zymosan from fungal
cell wall
TLR7
Myeloid cells, NK cells, endothelial
cell, T cells, B cells
Single-strand RNA (ssRNA)
compounds, such as the
imidazoquinolines
TLR8
Myeloid cells, NK cells, endothelial
cell
Single-stranded RNA (ssRNA)
TLR9
Myeloid cells, T and B cells, NK
cells, endothelial cells, epithelial
cells, keratinocytes
Unmethylated CpG motifs found in
microbial DNA
TLR10
Myeloid cells, T and B cells,
endothelial cells, epithelial cells
Unknown, may interact with TLR2
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1.2.5 Chemokines and cytokines in inflammation
As part of the immune response, granulocytes as well as other cells are able to
secrete cytokines and chemokines to aid in host defence, in addition to their other
factors. Chemokines are a number of small (8-10kDa), inducible, pro-inflammatory
proteins and can be divided between an α-chemokine subfamily and a β-chemokine 
subfamily. In humans, members of the α-chemokine subfamily include interleukin-8 
(IL-8) and interferon-gamma-inducible protein-10 (IP-10; CXCL10), whereas
eotaxin, monocyte chemotactic protein-1 (MCP-1; CCL2), MCP-2 (CCL8), MCP-3
(CCL7), MCP-4 (CCL13), macrophage inflammatory protein-1α (MIP-1α; CCL3), 
MIP-1β (CCL4) and regulated upon activation, normal T cell expressed and secreted 
(RANTES; CCL5) make up the β-chemokine subfamily (Ben-Baruch et al, 1995;
Baggiolini et al, 1997). In inflammation, IL-8 has been identified as playing an
important role in neutrophil recruitment and activation. Studies have shown that anti-
IL-8 antibody treatment, in a model of LPS-induced inflammatory disease in rabbits,
prevented neutrophil-dependent tissue damage as well as neutrophil infiltration
(Harada et al, 1994). MCPs have been shown to attract monocytes, basophils and T
lymphocytes, but not neutrophils. These chemokines are also closely related to
eotaxin and MCP-2, 3 and 4 have been found to act on eosinophils (Baggiolini et al,
1997). It has also been observed that MCP-1 in addition to RANTES promotes mast
cell activation (Conti & DiGioacchino, 2001).
Cytokines play a critical role in mediating and regulating immune effector function.
They have multiple biologic activities and play a major role in host defence and in
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the pathogenesis of various diseases. Some cytokines are pro-inflammatory and can
act by worsening disease, whereas anti-inflammatory cytokines serve to reduce
inflammation and promote healing (Dinarello, 2000). Cytokines such as IL-4, IL-5
and IL-13 are secreted by Th2 cells (discussed in section 1.3.2) These cells are potent
activators of B lymphocytes; they also act as anti-inflammatory cytokines, IL-4
antagonises IFN-γ and the genes for pro-inflammatory cytokines such as IL-1, IL-6, 
IL-8, tumour necrosis factor-α (TNF-α) and MIP-1α can also be suppressed (Opal et
al, 2000). Whilst some cytokines have proven to be anti-inflammatory, the most
potent of these is IL-10 which inhibits the Th1 (see section 1.3.2) cytokines IL-2 and
IFN-γ, although Th1 and Th2 cell clones have been reported to produce IL-10 (Opal 
et al, 1998; Del Prete et al, 1993). Another cytokine, TGF-β, also has both pro- and 
anti-inflammatory effects. It is an important regulator of cell proliferation,
differentiation and formulation of the extracellular matrix. Although it suppresses the
differentiation of T cells and B cells and limits the production of IL-2, IFN-γ and 
TNF, it is less potent than IL-10 and has little or no effect on IL-1 production
(Letterio & Roberts, 1997). It is the balance between these pro-inflammatory and
anti-inflammatory cytokines that is thought to determine the outcome of disease.
Chapter 1 Introduction
Page 14
1.3 Adaptive immunity
The primary players involved in the adaptive immune system are antibodies, T
lymphocytes, B lymphocytes and antigen presenting cells (APCs). The effector
mechanisms involved are slower than those of the innate system and are based upon
the amplification of soluble products acting systemically (humoral immunity), the
requirement of direct cell-to-cell contact or the activity of cytokines and chemokines
acting in the cellular microenvironment (cell-mediated immunity).
The adaptive immune system mounts a specific response through direct activation by
antigens of lymphocytes bearing specific antigen receptors. There are four types of
lymphocytes based on phenotypic and functional differences; B cells, T cells, NKT
cells (discussed in more detail in section 1.4.8) and NK cells. Although the latter
resemble lymphocytes in their morphology, they lack specific antigen receptors but
are capable of killing virus-infected and tumour cells in a non-specific manner and
therefore play a role in the innate immune system.
1.3.1 T cell differentiation
All lymphocytes differentiate from common lymphoid stem cells in the bone marrow
along distinct pathways. For T cell development, precursor T cells must migrate to
the thymus where they are phenotypically distinguished by the expression of CD3
and CD4 or CD8 co-receptors. In the thymus they also undergo further maturation
and selection for expression of antigen receptors (Staal et al, 2001). B cells, on the
other hand, continue their differentiation into antibody producing cells in the bone
marrow.
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1.3.1.1 T cell receptors
T cell receptors (TCRs) belong to the immunoglobulin superfamily and are
composed of α and β or γ and δ chains. The potentially large numbers of antigen that 
organisms may encounter in their life span requires receptors with antigenic
specificity. The αβ and γδ TCR pairs are encoded by genes formed by rearrangement 
of variable (V), diversity (D) and junctional (J) gene elements. The expression of
CD4 or CD8 co-receptors is not common to all T cells. While the αβ T cells are 
CD4+ or CD8+, γδ T cells are negative for both of these (Ferrero et al, 2007).
1.3.1.2 Antigen presentation and T cell recognition
In order for T cells to fully mature they must undergo positive selection, whereby the
TCR expressed on their surface must successfully and appropriately bind to self
major histcompatibility complex (MHC) antigens (Petrie et al, 1995). These naïve T
cells are programmed to re-circulate through secondary lymphoid tissues such as
lymph nodes until they die or encounter their specific antigen (Butcher & Picker,
1996). These tissues collect antigen from epithelial surfaces, somatic tissues and
blood and present it to these naïve cells in the context of an APC, leading to the
formation of memory/effector cells. The main cell type responsible for antigen
presentation is the DC, where in the absence of ongoing immune responses patrol
through the blood, peripheral tissues, lymph and secondary lymphoid organs. Danger
signals, such as the triggering of TLRs by pathogens, results in the maturation of
DCs, transforming them into efficient APCs and T cell activators. In peripheral
tissues, DCs take up self and non-self antigens which become internalised and
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processed into proteolytic peptides. These peptides are loaded onto MHC class I and
class II molecules and presented to T cells in secondary lymphoid organs
(Guermonprez et al, 2002).
Peptide recognition and the events which follow are carried out in a localised
environment between the TCR and APC called the immunological synapse, requiring
the activities of TCR – associated molecules, including co-receptors CD3 and CD8
or CD4, and other costimulatory receptors (Rudolph et al, 2006). The introduction of
antigenic peptide is essential for the differentiation of naïve T cells into effector T
cell subsets. Although already activated these T cell subsets require restimulation in
order to perform their function, whether that is via cytokines or cytotoxicity.
1.3.2 Th1 and Th2 cells
While in the thymus, T cells undergo differentiation into two distinct types of αβ T 
cells that exhibit different effector pathways, CD8+ cytotoxic T cells and CD4+ T
helper (Th) cells. Using the study of mouse CD4+ Th cell clones it was discovered
that these cells could be further subdivided into two subsets; Th1 and Th2 based on
their cytokine production (Mosmann et al, 1986). It has now been demonstrated that
these two types of cells regulate different immune responses. In studies using mice it
has been shown that Th1 cells produce large amounts of the pro-inflammatory
cytokine IFN-γ and are thought to mediate cellular immunity while Th2 cells instruct 
humoral immune responses by producing IL-4, IL-5, IL-10 and IL-13 that regulate B
cell proliferation and antibody class switching (Dong & Flavell, 2001). There are
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also several molecules important during cell migration found on these cells that may
also distinguish them such as CC chemokine receptor (CCR)5 and CXC chemokine
receptor (CXCR)3 on Th1 and CCR3 and CCR4 on Th2 cells (Mackay, 2000).
In addition to the Th1 and Th2 subtypes, early mouse studies demonstrated another
group of cells which have the capacity to produce all these cytokines and has been
described as Th0 (Firestein et al, 1989), representing an intermediary in the
differentiation of naïve T cells into Th1 or Th2. Studies investigating the factors
influencing the differentiation pathway have revealed that in the presence of IL-4, the
development of human T cells producing IL-4 and IL-5 (Th2) is favoured whereas
the addition of IFN-γ and anti-IL-4 antibody in culture supported the differentiation 
of T cells able to produce predominantly IFN-γ (Th1) via IL-2 blockade (Maggi et al,
1992; Ghoreschi et al, 2011).
1.3.3 The role of Th1 and Th2 cells in inflammatory disorders
Researchers have applied the defined T helper subsets in order to characterise the
mechanisms of certain disease processes. These effector T cells are key players in
driving immune responses. Th1 cells are involved in the protection of the host from
obligate intracellular pathogens, whilst Th2 cells are important in resistance to
extracellular forms of pathogens. Dysregulation of T helper cell responses can lead to
tissue damage and elicit unwanted chronic immune disorders such as allergy and
autoimmunity. The Th2 cells are well known to be involved in allergic disease,
examples of this are asthma and allergic rhinitis where peripheral blood mononuclear
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cells (PBMCs) from atopic patients (individuals sensitized to environmental
allergens) showed high levels of the Th2 cytokine IL-4 which was again correlated in
their mRNA expression (Esnault et al, 1996). In asthma where there is chronic
inflammation in the lungs, excess mucus secretion contributes to airway obstruction.
The receptors IL-4R and IL-13R share a common receptor chain, IL-4Rα, it has been 
shown that even in the absence of IL-4 there is still production of mucus. Another
cytokine, IL-13, may be the important Th2 cytokine involved in this, in addition to
the requirement of IL-4Rα (Cohn et al, 1999).
In other chronic inflammatory diseases we see a different cytokine profile, that of the
Th1 cells. These cells have been linked to conditions such as the inflammatory skin
disease Psoriasis vulgaris where lesional and peripheral blood T cells have
dominating Th1 cytokines (IFN-γ as well as high levels of TNF-α and IL-2) with 
very low levels of cells expressing IL-4 (Austin et al, 1999). The balance between
Th1 and Th2 cells in disease has been hotly debated and now these views have been
challenged by the emergence of a new subset of T helper cells and they may also
play a role in the environment of an inflammatory response (Steinman, 2007).
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1.4 Th17 effector cells
As previously described, much attention has been placed on the role of Th1 and Th2
cells in protecting against infection and the imbalance between the two subsets that
accounts for different immune pathologies. Certain disease processes could not be
explained as being mediated by Th1 or Th2 cells, especially when determining T-cell
mediated tissue damage (Steinman, 2007). The question remained what other cells or
cytokines could be contributing to this process? More recently there has been the
emergence of another CD4+ effector T cell subset termed Th17, so called for its
ability to secrete IL-17 and other pro-inflammatory cytokines. This discovery
evolved from studies focussing on two structurally related but functionally distinct
cytokines, IL-23 and IL-12. IL-23 has been reported to be essential for the expansion
of IL-17 producing T cells (Aggarwal et al, 2003; Langrish et al, 2005), while it is
accepted that IL-12 is responsible for the differentiation of naïve CD4+ T cells into
IFN-γ producing cells (Th1) (Wu et al, 1993). These studies have now indicated that
IL-23 is involved in playing a role in the pathogenesis of certain diseases such as
experimental allergic encephalitis (EAE) (Cua et al, 2003). This same group later
went on to show that IL-23 drives an IL-17 producing CD4+ T cell population, that
when transferred into recipient WT mice showed severe clinical signs of EAE
compared to IL-12-driven Th1 cells (Langrish et al, 2005). With the identity of the
IL-17 family of cytokines (IL-17A - IL-17F) it soon became evident that Th17 cells
and its associated cytokines are thought to have an important function in
inflammatory disease.
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1.4.1 Th17 cell differentiation
Many of the reports investigating Th17 cells and IL-17 have utilised mouse models.
It is now clear that the Th17 cell phenotype, origin and the role it plays in disease
differs from that of humans. In mice it has been shown that, following the actions of
transforming growth factor (TGF-β) and IL-6, naïve CD4+ T cells differentiate into
Th17 cells with IL-23 acting to stabilise the phenotype (Bettelli et al, 2006; Mangan
et al, 2006; Veldhoen et al, 2006). Recently conflicting data have revealed that in
humans differentiation into the Th17 cell subset requires IL-1β, IL-6 (Acosta-
Rodriguez et al, 2007), IL-21 or IL-23 and TGF-β (Manel et al, 2008; Volpe et al,
2008). In their findings that IL-1β and IL-6, in the absence of TGF-β, is sufficient for 
Th17 differentiation, Acosta-Rodriguez et al also reported that the addition of TGF-β 
has an inhibitory affect on the number of IL-17 producing cells. There is also the
suggestion that not only can Th17 differentiation occur without TGF-β (IL-1β plus 
IL-23 being effective) but this cytokine supports the development of Th17 cells by
inhibiting IFN-γ producing cells (Th1) (Santarlasci et al, 2009).
Human Th17 cells have also been characterised by Acosta-Rodriguez and colleagues
as cells that express the chemokine receptors, CCR6 and CCR4 and produce IL-17.
These CCR6+ CCR4+ Th17 cells also expressed mRNA to the human ortholog of
mouse RORγt (RORC variant 2), which is required for Th17 cell differentiation 
(Acosta-Rodriguez et al, 2007). CCR6 has been shown to be involved in the
recruitment of dendritic cell populations as well as Th17 cells to inflamed sites via
the ligand CCL20 (Dieu-Nosjean et al, 2000; Hirota et al, 2007).
Chapter 1 Introduction
Page 21
1.4.2 Th17 cells in immunopathology
The pathogenic role of Th17 cells in humans has been widely studied to date. It has
now been implicated in certain diseases although only established in a condition
known as Hyper-immunoglobulin E syndrome (HIES) (Annunziato et al, 2008).
HIES or Job’s syndrome is a primary immune deficiency characterised by an
abnormal susceptibility to infections (Ma et al, 2008). This study found that STAT3
mutations from CD4+ T cells of HIES patients had a defect in Th17 differentiation
and therefore are seen as the causative agent in HIES patients’ inability to defend
against certain pathogens (Ma et al, 2008). This further underscores the belief that
Th17 cells are thought to play a role in host protection against extracellular
pathogens.
The role of Th17 cells in human chronic inflammatory disease is not so definitively
established. It has been demonstrated that IL-17 is present in biopsies from lesional
psoriatic skin which for many years was considered a Th1 disease with IFN-γ 
playing a key role (Austin et al, 1999; van Beelen et al, 2007). As well as psoriasis, it
has been shown that there is an infiltration of Th17 cells in tissues of Crohn’s
disease, rheumatoid arthritis and allergic asthma (Pène et al, 2008). This interplay
between Th1 and Th17 cells in disease is again echoed in another report where
researchers found that in experimental autoimmune uveitis (EAU) disease is
inhibited when mice are treated with anti-IL-17 and in the absence of an IFN-γ 
response, Th17 effector cells still have the capability of inducing EAU. Th17 cells in
this instance were thought to play a more dominant role, but when cells from a
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uvetitogenic CD4+ Th1 cell line were given to naïve syngeneic mice, EAU was
induced (Luger et al, 2008). Although these discoveries are very insightful they do
not produce a clear picture of the role of Th17 cells in inflammatory disorders. These
cells produce several inflammatory cytokines but at the moment we cannot be sure
which of these cytokines contribute to the inflammatory process in man and hence
disease pathogenesis (Annunziato et al, 2008).
1.4.3 The IL-17 family of cytokines
Th17 cells are capable of producing various cytokines such as IL-22, IL-26 and
TNF-α, one of their main effector cytokines is IL-17A, and its production in humans 
was first described in activated human peripheral T cells (Langrish et al, 2005; Yao
et al, 1995). The IL-17 family of cytokines consists of six family members, IL-17A –
IL-17F, with IL-17F being the other main cytokine secreted by human Th17 cells
(Shen & Gaffen, 2008). Other cell types that are thought to produce IL-17 are NKT
cells and γδ T cells (described in section 1.4.8); in mice it has been shown that γδ T 
cells are thought to be important in providing a protective response to
Mycobacterium tuberculosis via their production of IL-17A (Lockhart et al, 2006). In
humans it has been observed that a large proportion of IL-17 producing cells in the
peripheral blood consists of γδ T cells, which become the vast majority of the IL-17+
population in tuberculosis patients (Peng et al, 2008).
Another prominent member of the IL-17 family, which in the last few years has been
the focus of much work, is IL-17E (IL-25). Unlike IL-17A and IL-17F, this cytokine
has been found to be secreted by lung epithelial cells and has been implicated in
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initiating Th2 type immunity by driving the expression of IL-4, IL-5 and IL-13
(Angkasekwinai et al, 2007; Fallon et al, 2006). A proposed model for the actions of
these IL-17 family members during allergic inflammation has been described in
Figure 1-2.
Figure 1-2 Diagram demonstrating the effector mechanisms of the IL-17 family of cytokines.
The invasion of the epithelium by virus, fungi and allergens induces the infiltration or differentiation
of IL-17 producing T cells. These cells release IL-17A, IL-17F and IL-22, inducing structural cells
such as the epithelium to secrete large quantities of inflammatory cytokines and chemokines leading
to the recruitment of other cells such as neutrophils to the site of injury. During chronic inflammation,
mast cells, basophils and eosinophils infiltrate the area, which along with damaged structural cells
secrete IL-25 and increase Th2 cytokine production from Th2 cells activated by antigen loaded DCs
(Taken from Wang & Liu, 2008).
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1.4.4 The family of IL-17 receptors
There are currently five members of the IL-17 receptor family (IL-17RA-RE) that
display differing biological effects upon binding to their ligand, ranging from
cytokine secretion and neutrophilia to mucus secretion (Wang & Liu, 2008). Within
this family there is significant sequence divergence, although many of the genes
encoding these receptors are linked, with clusters found on human chromosome 3.
All the receptors contain a single transmembrane domain which range in size from
499-866 amino acids (Gaffen, 2009). These receptor subunits have conserved
structural motifs which include an extracellular fibronectin III-like domain and a
cytoplasmic tail encoding a SEF/IL-17 receptor (SEFIR) domain (Figure 1-3), which
bears some homology with the TIR domains of TLRs (Onishi et al, 2010). Most of
the IL-17 receptor family members exhibit broad distribution; earlier reports from
mouse cells and cell lines have detected IL-17R mRNA in liver epithelial cells,
fibroblasts and mast cells amongst others (Yao et al, 1995). It has now been shown
that human fibroblasts, epithelial and endothelial cells coexpress both IL-17RA and
IL-17RC, whilst T cells only express IL-17RA (Ishigame et al, 2009).
IL-17RA is a common signalling subunit used by multiple ligands (Figure 1-3).
Studies on human IL-17R have demonstrated that, in order for IL-17A and IL-17F to
elicit a response, IL-17RA (also known as IL-17R) and IL-17RC are necessary
(Wang & Liu, 2008). More recently it has been shown that although IL-17A, IL-17F
and a heterodimer of IL-17F/IL-17A all bind to IL-17RA albeit at differing binding
kinetics, they bind to IL-17RC at similar rates. The results also showed that IL-17A
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binds better to IL-17RA than IL-17RC with the opposite being true for IL-17F, while
IL-17F/IL-17A binds with similar affinity to both receptors (Wright et al, 2008).
Unlike TLRs which utilise the adaptors MyD88 and TRIF, IL-17 signals through the
Act1 adaptor and U-box E3 ubiquitin ligase that contains both a SEFIR and TRAF
domain (Gaffen, 2011). Stimulation of IL-17 receptors results in the activation of
NFκB, MAP kinases and possibly PI3K. Other transcription factors such as IκBζ and 
C/EBP have also been reported to be activated (Gaffen, 2011).
To date the most studied of the receptors is IL-17RA and IL-17RC, although recent
work has sought to identify the ligands and signalling components of the other
receptors. IL-17RB is expressed by various endocrine tissues as well as the kidney,
liver and Th2 cells. This receptor alone binds both IL-17B and IL-25; it can also pair
with IL-17RA to form a functional IL-25R complex. Like the rest of the family, the
cytoplasmic tail of IL-17RB contains a SEFIR domain and has been reported to bind
Act1 in a SEFIR-dependent manner (Chang & Dong, 2011). It is difficult to
speculate on the other family receptors as they have not been studied in depth. The
literature at the moment has been unable to identify a ligand for IL-17RD. So far it
seems to be the oldest member of the IL-17R family and can interact with IL-17RA,
although the biological significance of this relationship is not clear. IL-17RE remains
the least understood receptor (Gaffen, 2009).
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1.4.5 Th9 cells
Since the emergence of Th17 cells, two further T helper cell subsets have come to
light. The principal cytokine secreted by Th9 cells is IL-9, although it can also be
secreted by other cell types such as mast cells, eosinophils and neutrophils (Soroosh
& Doherty, 2009). Initially it was revealed that IL-9 is preferentially produced by
Th2-like lymphocytes (Dugas et al, 1993). Later reports showed that activation of
naïve CD4+ T cells, in the presence of IL-4 and TGF-β significantly increased IL-9 
and IL-10 production but not other Th2 cytokines, indicating a population distinct
from Th2 cells (Veldhoen et al, 2008; Dardalhon et al, 2008). It is now thought that
IL-9 may play a role in allergic airway disease. In mouse models, transgenic mice
over-expressing IL-9 were found to have increased airway-hyperresponsiveness,
eosinophilia and IgE levels after antigen challenge (McLane et al, 1998). In humans,
bronchial biopsies from patients with atopic asthma have shown an elevated number
of IL-9 mRNA-positive cells in the airway compared with normal controls (Ying et
al, 2002). With the many sources of IL-9, it is difficult to draw conclusions as to the
presence or role of Th9 cells in allergic disease.
1.4.6 Th22 cells
The defined Th22 cells were first thought to be a variant of Th17 cells, it has now
been shown that IL-22 can be produced without production of IL-17 (Nograles et al,
2009). IL-22 belongs to the IL-10 cytokine family and has both pro-inflammatory
and protective properties although its actions are not fully understood. The response
to IL-22 normally comes from nonhematopoietic cells such as epithelial cells and
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keratinocytes, as they express IL-22R. This triggers the production of antimicrobial
peptides and expression of proteins involved in cellular differentiation and survival
(Souwer et al, 2010). A pathogenic role for IL-22 has been proposed by studying IL-
22 deficient mice, where a decreased incidence of disease was observed in an
arthritis model (Geboes et al, 2009). In atopic dermatitis skin, an upregulated
expression of IL-22 has also been reported (Nograles et al, 2009). More research is
needed to further elucidate the function of IL-22 in allergic disease.
1.4.7 T regulatory cells
The host immune system also has specific cells that are involved in the regulation of
immune responses. During the past decade, T regulatory (Treg) cells have emerged
as key players in the development of immunological tolerance. Dysfunction of this
cell can cause autoimmune disease, immunopathology and allergy (Sakaguchi et al,
2008). Tregs are naturally occurring and are characterised as CD4+ CD25+ cells
(although in human studies, it has been argued that CD25 is not a definitive marker)
expressing the transcription factor forkhead box P3 (FoxP3). They are capable of
suppressing the activation and proliferation and effector functions of a wide range of
immune cells such as, CD4+ and CD8+ cells as well as NK and NKT cells. Currently,
the use of Treg cell-based therapy is the subject of much research for the application
of immunological disease (Sakaguchi et al, 2010).
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1.4.8 Unconventional lymphocytes
There are other lymphocytes that also contribute to the immune defence towards
invading pathogens; these lymphocytes take the form of γδ T cells and NKT cells. In 
contrast to the more conventional αβ T cells previously discussed, a population of 
lymphocytes bearing a new TCR heterodimer, γδ, was discovered (Brenner et al,
1986). This lymphocyte subset acts in a way very distinct from αβ T cells, especially 
in its recognition of antigen. Although sharing certain cell surface proteins with αβ T 
cells, the interaction of γδ TCR with its ligand is more akin with antigen – antibody 
interactions, unlike the processing and presentation of antigen required for αβ T cells. 
The ability to recognise intact proteins directly is a characteristic of γδ T cells, 
enabling them to mediate their cellular immune functions faster than αβ T cell 
mediated immunity (Chien et al, 1996). The distribution of γδ T cells in humans is 
greater in the skin and mucosa, than in lymphoid organs or peripheral blood
(Kaufmann, 1996). In response to antigenic stimulation, these cells can secrete
cytokines and also take part in cytolytic activities. Studies in mice have found that
they are capable of regulating the development of epithelial cells and αβ T cell 
responses (Komano et al, 1995; Kaufmann et al, 1993). More recent reports have
observed the secretion of IFN-γ, IL-10 and high levels of TGF-β in human γδ T cells, 
and have subsequently been implicated as having potent regulatory potential (Kühl et
al, 2009).
NKT cells are a population of lymphocytes that share some characteristics with NK
cells. They are innate-like T lymphocytes that recognise glycoproteins in the context
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of CD1d, the MHC class I-related glycoprotein (Van Kaer, 2007). There are two
subtypes of NKT cells; type I NKT cells, also known as invariant NKT (iNKT) cells,
have a highly restricted αβ TCR repertoire. In comparison, the TCR repertoire 
expressed by type II NKT cells is more diverse (Umetsu & DeKruyff, 2010; Van
Kaer, 2007). In the healthy human liver, NKT cells make up 0.5% of CD3+ cells and
in the blood, 0.02% (Kenna et al, 2007). Most studies have focussed on iNKT cells,
which upon activation have been found to produce high levels of IL-4, IFN-γ and 
TNF and can thereby activate DCs, NK cells B cells and conventional T cells
(Umetsu & DeKruyff, 2010). In systemic lupus erythematosus, iNKT cells are also
thought to play a pathogenic role (Major et al, 2006), later studies have now
implicated these cells in allergic airway inflammation. In human asthma, increased
numbers of iNKT cells have been observed, especially in patients with severe
asthma. Some investigations have also reported contradictory findings in asthma
patients (Iwamura & Nakayama, 2010). Further to this, some authors have suggested
that these cells do not drive asthma pathogenesis but in fact modulate the asthmatic
phenotype (Thomas et al, 2010).
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1.5 Dysregulation of the immune response
In its aim to protect the body against disease, the immune system can sometimes
cause harmful reactions in the host. Such reactions are known as hypersensitivity
reactions, which can be divided into four types as originally conceived by Gell and
Coombs (Gell & Coombs, 1963). Immediate hypersensitivity reactions (Type I)
occur within minutes after contact with the antigen. A localised reaction usually
ensues if the contact involves the epithelial tissues, such as that found in asthma or
allergic rhinitis (hay fever). The reactions are commonly referred to as allergic and
the antigens involved are allergens. This type of hypersensitivity is mediated by IgE
which precedes the release of histamine and other mediators from mast cells and
basophils.
Cytotoxic reactions (Type II hypersensitivity) are another form; in this case, IgG or
IgM antibodies which bind to cell surface antigens leading to complement activation
and destruction of local tissue cells. Antigens and antibodies may also form
complexes that enter into the circulation and again can activate the complement
system and cause local tissue damage. This type III hypersensitivity response is also
known as immune – complex reactions.
The last group of hypersensitivity reactions are mediated by T cells rather than
antibodies and is termed delayed hypersensitivity (Type IV). As opposed to
immediate hypersensitivity, this reaction takes a day or more to develop. The
responding T cells secrete chemokines that attract macrophages which take part in
phagocytosis and subsequent tissue destruction (Rajan, 2003). Allergic disorders that
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affect the ocular surface are generally thought to be classed as either type I or type
IV hypersensitivity reactions – depending on the location and the degree of severity.
1.6 A role for the epithelium in adaptive immunity
As part of their innate function, epithelial cells produce a repertoire of cytokines and
chemokines, which can be released into the local environment during mechanical
injury, for example as a result of virus or bacterial invasion. Many studies have been
conducted with the use of human colon and bronchial epithelial cells, to investigate
their expression and production of cytokines and chemokines. These studies have
demonstrated mRNA transcripts for IL-8 and TGF-β1, even in the absence of 
stimulation, as well as detectable levels of TNF-α, IL-1α, IL-1β, IL-10, GM-CSF and 
MCP-1, and of these, IL-8, MCP-1, TNF-α and GM-CSF can be upregulated in the 
presence of TNF-α stimulation or infection by certain bacterial strains (Jung et al, 
1995). Within an asthma setting, bronchial epithelial cells from asthmatic patients
have been shown to produce high levels of GM-CSF, IL-6 and IL-8 (Marini et al,
1992).
Within the last few years, the emergence of an epithelial derived cytokine called
thymic stromal lymphopoietin (TSLP) has provided researchers with further
evidence of a larger role for epithelial cells in the immune response. Thymic stromal
lymphopoietin (TSLP) is an IL-7 – like, epithelial cell-derived cytokine that was first
characterised in murine models of B cell development, where it was found to be an
important factor in supporting the growth of B cells as well as exhibiting the ability
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to induce the expansion of B220+ pre-B cells (Sims et al, 2000). The functional
receptor for this cytokine has already been characterised in the mouse. In human
models this receptor complex is similar, consisting of two subunits – TSLPR and IL-
7Rα – which have been found to be specific for TSLP and not IL-7, and which upon 
ligation lead to subsequent signal transducer and activator of transcription (STAT) 5
and STAT3 phosphorylation (Reche et al, 2001). Studies on the mRNA of this
receptor have shown that its expression is restricted to DCs, monocytes, some T cell
clones and more recently mast cells (Reche et al, 2001; Allakhverdi et al, 2007).
Studies using mouse models of allergic skin inflammation have shown that TSLP is
vital for Th2 cytokine secretion by skin infiltrating effector T cells (He et al, 2008).
The biological properties of TSLP differ between humans and mice and therefore the
main focus here will be on the role of TSLP in modulating the human immune
response. Analysis of mRNA has found that TSLP is not expressed by human
endothelial cells or hematopoietic cell types such as B cells, T cells, NK cells or
granulocytes, its expression is mainly by epithelial cells, stromal cells and mast cells
(Soumelis et al, 2002).
Unlike murine TSLP, there have been no reports that human TSLP promotes the
development of B and T cells although it has been shown to enhance the maturation
of CD11c+ DCs as well as slightly upregulating HLA-DR and CD86 expression and
strongly inducing the co-stimulatory molecules CD40 and CD80 (Reche et al, 2001).
In conjunction with each other, CD11c+ DC in the presence of TSLP can provoke a
very strong naïve T cell proliferation (Reche et al, 2001).
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The microenvironment created by the presence of TSLP has also been studied and in
mouse models it has been shown that this cytokine can drive Th2 development
directly without any need for antigen presenting cells (APCs) (Omori & Ziegler,
2007). In addition, Ying et al observed that in diseases such as asthma there is a
significantly increased expression of the mRNA of Th2 attracting chemokines
TARC/CCL17 in the epithelium and submucosa which also correlated with the
expression of TSLP in those areas. A role for TSLP in Th2 differentiation through
the actions of TSLP stimulated DCs (TSLP-DCs) has been also been proposed. The
mechanisms behind this polarising effect are thought to be due in part through OX40
ligand (ligand for the CD4 activation antigen OX40). Ito et al have demonstrated that
TSLP-DCs expressing OX40L are responsible for the differentiation of CD4+ T cells
into Th2 cells (Ito et al, 2005). The actions of TSLP may elicit many effects as part
of the epithelial response (Figure 1-4), although problems may arise – as seen with
the secretion of other pro-inflammatory cytokines – if this response becomes
exaggerated.
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Figure 1-4 Diagrammatic representation of the effect of TSLP secretion in response to
microbial invasion. Damage to the epithelium by pathogens leads to the secretion of TSLP by
epithelial cells, this in turn upregulates the costimultory molecules OX40, CD40 and CD80 on
DCs which are involved in T cell polarisation to the Th2 phenotype. The secretion of Th2
cytokines induces B cell IgE production leading to the activation of mast cells. IL-1 and TNF-α 
produced by the damaged epithelium also activates mast cells to secrete TSLP – thereby feeding
back into the loop – and other cytokines, which along with IL-5 and GM-CSF produced by Th2
cells allow the recruitment of eosinophils (Taken from Holgate, 2007).
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1.7 The ocular surface
The surface of the eye is the most exposed mucous membrane of the body (Buckley,
1998), coming into direct contact with the environment containing airborne debris or
pathogens. It is therefore vital that there is some form of protection from these
foreign particles. There are many layers that allow for this protection, of these the
eyelid forms the outermost guard for the anterior of the eye. The exposed ocular
globe is covered by the pre-ocular tear film which contains substances with
bactericidal properties. Tearing also provides a flushing and cleansing action to
remove foreign particles or noxious chemical substances (Holly, 1987). Beyond this
a vascularised mucous membrane is revealed covering the anterior surface of the
eyeball and the posterior surface of the upper and lower eye lids, known as the
conjunctiva (Hoang-Xuan et al, 2001).
1.7.1 The conjunctiva
The conjunctiva is a membraneous junction between the lids and the globe of the
eye; it ensures smooth movement of the eyelids over the globe (Figure 1-5A). It
transitions from the skin of the lid margin where it lines the inner surface of the lids,
is reflected beyond the tarsal plate and lies against the surface of the sclera, with
which it fuses at the corneo-scleral junction therefore forming a conjunctival sac or
fornix (Spooner, 1976). The tissue lining the eyelid is known as the palpebral
conjunctiva which has a stratified non-keratinising squamous epithelium that is
continuous with the keratinised squamous epithelium of the epidermis of the eyelid
(Hoang-Xuan et al, 2001). The bulbar conjunctiva covers the sclera; it is thin and
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translucent, allowing the sclera to show through. It loosely adheres to the underlying
tissue within 3mm of the cornea. The fornix connects both these sections (Figure 1-
5B).
The conjunctival glands are a number of small glands that participate in tear film
secretion. The palpebral sebaceous glands contain meibomian glands, their secretions
form the outermost lipid layer of the tear film, and Zeiss glands which release sebum
into the eyelash follicle preventing the cilia from becoming dry and brittle
(Remington, 1998). Within the fornix the ducts of the lacrimal gland and the
accessory lacrimal glands can be found, the latter of which is separated into two
groups according to the type of secretion (serous or mucous). The serous glands
include the glands of Krause comprising of about 20 to 40 such glands in the
superior fornix and 6 to 8 in the inferior and the glands of Wolfring or Ciaccio with
no more than 6 being found in the upper lid and 2 located in the inferior edge of the
lower tarsus. Henle’s glands or crypts are part of the mucous glands; they arise in the
palpebral conjunctiva between the tarsal plates and the fornices. They are composed
of goblet cells which secrete mucus and form folds of mucous membrane lined by
epithelium. The limbus houses Manz’s glands found in many animal species but not
present in humans (Spooner, 1976; Hoang-Xuan et al, 2001).
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1.7.2 The conjunctival epithelium
The epithelium of the conjunctiva is composed of between 2 and 10 layers of cells
and, depending on its location, the size and shape of these cells are variable (Hoang-
Xuan et al, 2001). Over much of the upper lid the epithelium is 2 to 3 cells thick
whereas the lower lid is thicker with 3 to 4 cells (Remington, 1998). There are four
distinct morphological components comprising the conjunctival epithelium. The
eyelid has previously been described to be of a nonkeratinised and keratinised
stratified squamous epithelium covering a connective-tissue stromal layer, the
submucosa (Remington, 1998). Other areas such as the bulbar conjunctiva have a
stratified epithelium with cylindrical superficial cells with other sites containing
flattened superficial cells. In some cases, as the epithelium continues along it may
change from a columnar to a squamous morphology.
Once again there are goblet cells, in this case scattered throughout the stratified
columnar epithelium. Their number tends to decrease with age and greatly increases
in some inflammatory conditions such as vernal conjunctivitis and contact lens-
associated giant papillary conjunctivitis (Dartt, 2004). They are thought to be formed
from the deepest layer of the conjunctiva, the cylindrical cells, where they pass
towards the surface. They play an important role in moistening and protecting the
conjunctiva and cornea via their production of mucins (Wolff, 1976).
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1.7.3 Allergic conjunctivitis
Currently there are a few basic types of ocular allergy that constitute allergic
conjunctivitis – which refers to a collection of hypersensitivity disorders – affecting
about 20% of the population worldwide (Trocme & Sra, 2002). Allergic
conjunctivitis can be divided into two main groups depending on the patients’ signs
and symptoms. The first group, also known as a milder disorder is more frequent and
includes perennial (PAC) and seasonal allergic conjunctivitis (SAC), the latter of
which is usually the ocular component of hay fever. The second group and the more
severe form of allergic conjunctivitis have been given the term ‘chronic allergic eye
disease’ (CAED) and it mainly describes two types, vernal keratoconjunctivitis
(VKC) and atopic keratoconjunctivitis (AKC). Both forms are less frequent and the
disease may be complicated by corneal involvement (Leonardi et al, 2008). The
common clinical features of allergic conjunctivitis include redness, itching and
tearing, there also tends to be eosinophil recruitment to the ocular surface (Stahl &
Barney, 2004).
1.7.4 Seasonal allergic conjunctivitis
As discussed, one of the most prevalent forms of ocular allergy is SAC. In the UK it
affects up to one-fifth of the adult population and represents the majority of all ocular
allergy cases, with 98% of patients with ocular allergy having SAC or PAC.
Although having similar characteristics, PAC differs from SAC as it is the rarer of
the two and is caused by a constantly present allergen such as the house-dust mite as
opposed to season-related pollens (Buckley, 1998). SAC is characterised by an IgE-
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mediated response to environmental airborne allergens, such as grass and tree
pollens. The binding of these allergens to specific IgE occurs on conjunctival mast
cells – the main responding cell type in this disorder – and results in mast cell
degranulation and their release of histamine, tryptase, prostaglandins and
leukotrienes. Histamine in particular is the principal mediator thought to account for
the itching, redness and swelling that are the hallmark signs of this disorder (Ono &
Abelson, 2005).
Mast cells are particularly influential in the inflammatory response observed in SAC
as the histamine and leukotrienes that they release are thought to contribute to the
recruitment of neutrophils and eosinophils (Spada et al, 1986; Woodward et al,
1986). A correlation between these cells and adhesion molecule upregulation has
been observed in atopic subjects challenged with allergen. This study demonstrated
that 6 hours after allergen challenge, the expression of E-selectin and ICAM-1 was
upregulated and there was infiltration of mast cells, neutrophils, eosinophils and
macrophages compared to that of the control where infiltrating cells were not present
(Bacon et al, 2000).
1.7.5 Vernal keratoconjunctivitis
This form of CAED is a disease that affects mostly young people, it is also more
common in males and visual impairment may occur if the cornea is involved.
Sufferers have a history of atopic disease in 49% of cases (Bonini et al, 2004) and, as
such, some symptoms and cells (itching, redness and degranulated mast cells) are
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similar to SAC, but there are major differences as VKC is a more chronic and severe
form of ocular allergic disease. Clinical features of VKC include the presence of
giant papillae on the upper tarsal conjunctiva or at the limbus and transient limbal or
conjunctival yellow – white points or deposits known as Horner – Trantas dots which
are clumps of eosinophils and epithelial cell debris (Kumar, 2009). The tissues from
VKC may also undergo remodelling such as thickening of the conjunctival
epithelium or epithelial loss which may be attributed to connective tissue deposition,
oedema or inflammatory cell infiltration (Leonardi, 2002). The majority of VKC
cases are seasonal and last from the beginning of spring until autumn, although there
are perennial cases that persist throughout the year particularly in patients living in
warm sub-tropical or desert climates (Leonardi, 2002). In the UK 75% of those
affected have a history of atopic disease whilst 67% have a family history of atopy
(Buckley, 1998).
Whilst the conjunctival epithelium and stroma are infiltrated with mast cells and
neutrophils, T lymphocytes and eosinophils are the predominant cell type in VKC. T
lymphocytes have been regarded as one of the principal mediators in the
pathogenesis of this disorder. The phenotypic characteristics of VKC are marked by
infiltration into the conjunctiva of CD4+ CD45RO+ T lymphocytes, with upregulated
expression of HLA-DR in allergic tissues compared to normal controls. This
expression was also observed on other cell types including macrophages, DCs and
epithelial cells (Metz et al, 1996). Conjunctival specimens from VKC subjects have
shown increased numbers of inflammatory cells that are positive for the chemokine
receptor CXCR3, demonstrating a possible regulation of lymphocyte recruitment
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within the conjunctiva of patients affected with this disorder (Abu-El Asrar et al,
2001). As well as the majority of T lymphocytes being CD4+, an early report from
Maggi and colleagues observed conjunctival tissue-derived T cell clones derived
from VKC patients when stimulated were mainly producing IL-4, indicating that Th2
cells are the predominant cell type in this disease (Maggi et al, 1991). Later studies
revealed increased mRNA expression of IL-3, IL-4 and IL-5 in the tissues of VKC
patients and in the tears of these patients, there was an increased percentage of CD4+
T lymphocytes expressing IL-4, which was thought to correlate with disease severity
(Metz et al, 1997; Leonardi et al, 1999). Although being a very severe disease, VKC
usually resolves at puberty but it can sometimes transform into AKC.
1.7.6 Atopic keratoconjunctivitis
Of all the ocular surface allergy–related disorders AKC is the most severe and
chronic form. It is associated with atopic dermatitis and affects the conjunctiva and
the lids of the eye (Bielory, 2000). The condition occurs in both children and adults
although the onset is usually between 20 and 50 years of age (Stahl & Barney, 2004).
The clinical signs include hyperaemia of the conjunctiva and papillae on the upper
tarsal conjunctiva, in very severe cases conjunctival scarring with subepithelial
fibrosis may occur and, like VKC, it can be sight threatening if there is corneal
involvement (Bonini, 2004). Unlike that of VKC, the inflammatory cell infiltrate in
AKC are predominated by CD4+ T cells and neutrophils, with fewer eosinophils and
mast cells than VKC. Where the two disorders differ is in their cytokine profile and
hence the distribution of Th1 and Th2 cells. The same studies that detected large
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numbers of IL-4 producing CD4+ T cell clones in VKC also noted that there were a
limited number of IFN-γ producing T cells, whilst in AKC the expression of IFN-γ 
localised to T cells was greater than in VKC, giant papillary conjunctivitis (GPC)
and the controls (Maggi et al, 1991; Metz et al, 1997; Calder et al, 1999). These
studies indicate that there is a shift towards a more Th1 cell population in this
disorder.
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The cytokines and other molecules upregulated as a result of foreign invasion are
important in the inflammatory response especially for recruitment of cells to the site.
It has already been shown that normal conjunctival epithelial cells secrete a range of
cytokines such as IL-6, IL-8, TNF-α and RANTES that when upregulated, contribute 
to this process. During chronic inflammation such as that seen in CAED,
conjunctival epithelial cells have also been shown to have greater expression of
ICAM-1 and HLA-DR (Hingorani et al, 1998). Other cells infiltrating the
conjunctiva contribute to changes in the cytokine environment during disease.
Conjunctival T cells from subjects with CAED have increased levels of IL-3, IL-4
and IL-5 although the two different forms of CAED have differing cytokine profiles.
In VKC conjunctival tissue sections, there is a Th2 like profile while in AKC it is
more Th1 like (Metz et al, 1997). In VKC conjunctival-derived T cell lines, there is a
mainly Th2 cytokine profile whereas in AKC conjunctival-derived T cell lines, there
is also a Th1 profile (Calder et al, 1999). Within other tissues such as that of the
lung, mRNA of an epithelial cell derived cytokine TSLP was reported to be
increased in asthmatics (Ying et al, 2005). This cytokine has also been implicated in
induction of Th2 attracting chemokines, thereby suggesting a role in asthma
pathogenesis (Soumelis et al, 2002).
In diseases such as psoriasis and allergic asthma, infiltrating Th17 cells have been
isolated in the tissues (Teunissen et al, 1998; Pène et al, 2008). These cells have also
been shown to produce several inflammatory cytokines and therefore have been
thought to contribute to chronic inflammatory diseases (Laan et al, 1999; Jones &
Chan, 2002). Mast cells play an important role in allergy. They produce a range of
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pro-inflammatory cytokines and chemokines – important in recruiting inflammatory
cells – and can also cause direct tissue damage via secretion of molecules such as
histamine and TNF-α. The hypothesis of my study is that conjunctival epithelial cells 
contribute to T cell effector mechanisms in CAED via the actions of their cytokines
and chemokines on T cells and mast cells.
To investigate this hypothesis, I will aim to:
I. Identify novel epithelial derived cytokines as well as other cytokines known
to be associated with tissue inflammation and their expression in
conjunctival tissues during disease;
II. Investigate whether tissues from the conjunctiva express Th17 cells and if
this is elevated during chronic eye disease.
I will examine the effect of co-culturing human T cells or mast cells with
conjunctival epithelial cells, using an in vitro model of human conjunctival epithelial
cells to establish the mechanism by which these cells and their cytokines and
receptors are potentially capable of causing disease pathogenesis.
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2.1 Culturing of human cells
2.1.1 In vitro culture of IOBA-NHC cells
A conjunctival epithelial cell line, IOBA-NHC (a kind gift from M. Calonge,
Valladolid, Spain) was incubated at 37oC, 5% CO2 in 5ml “IOBA” medium
containing DMEM Nutrient Mixture F-12 HAM (Sigma-Aldrich, Dorset, UK)
supplemented with 10% heat-inactivated foetal calf serum (FCS; Biosera, East
Sussex, UK), Penicillin/Streptomycin (P/S) (100U/ml; Invitrogen, Paisley, UK),
mouse endothelial growth factor (EGF) (2ng/ml; Sigma), bovine insulin (1µg/ml;
Sigma-Aldrich), hydrocortisone [5µg/ml] and Cholera Toxin (Sigma-Aldrich;
0.1µg/ml) in a 25cm2 flask (Diebold et al, 2003). At confluence the cells were
detached using trypsin-EDTA (Invitrogen) and incubated at 37oC, 5% CO2 for 3
minutes then centrifuged at 400rcf for 10 minutes and transferred to a 75cm2 flask in
10ml IOBA medium and incubated at 37oC, 5% CO2. Cells were split and fed when
cell monolayers became confluent.
2.1.2 In vitro culture of ChWK cells
The conjunctival epithelial cell line, Wong-Kilbourne derivative of Chang
conjunctiva-(ChWK; clone 1-5c-4 ECACC, Idmiston UK) was maintained in
Medium- 199 (Sigma-Aldrich) supplemented with 10% FCS, P/S (100U/ml) and L-
glutamine [2mM; Invitrogen] (Zhan et al, 2003). Upon reaching confluence, cells
were detached using trypsin-EDTA (Invitrogen) and routinely split into new flasks.
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2.1.3 In vitro culture of 16 HBE cells
The bronchial epithelial cell line, 16 HBE (a kind gift from P. Lackie, University of
Southampton, UK) was cultured as described in 2.1.2.
2.1.4 In vitro culture of human cord blood mast cells (CBMC)
Mast cells were generated from the culture of human cord blood CD34+ progenitors
(Lonza Wokingham Ltd; Berkshire, UK). Cells (2 x 105 approx per vial) were
cultured in 200µl StemSpan® medium (Stemcell Technologies, Grenoble, France)
supplemented with IL-3 [1ng/ml], IL-6 [50ng/ml] and stem cell factor (SCF)
[100ng/ml; all Peprotech, London, UK] and seeded onto a 96 well plate. Cells were
routinely split then transferred firstly to a 24-well plate (Nunc) until sufficient
numbers were then transferred to a 25cm2 flask and grown in 5-10 ml of culture
medium. After the first 2 weeks of culture, IL-3 was removed from the culture
medium and confluent cells were subsequently grown in 75cm2 flasks until 8 weeks.
From 9 weeks onwards, 10% FCS was introduced into the culture medium to aid in
the cells maturation. The cells were maintained at 1 x 106/ml (approx). At 11 weeks’
culture, cells were counted and stained for their expression of c-Kit (SCF receptor)
and FcεRI (IgE receptor), to determine phenotypically, if the cells had differentiated 
into mast cells.
2.2 Mast cell cytospins
To ascertain whether the mast cells contained the enzymes tryptase and chymase, 1 x
103 cells in 100μl of medium were placed into cytocentrifuge funnels with a slide 
attached and spun at 1000rpm for 3 minutes (Cytocentrifuge Cytospin 3; Fisher
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Scientific, Leicestershire, UK). The slides were removed and allowed to dry before
fixing in acetone for 1 minute, then stored for immunohistochemical staining.
2.3 Cytokine treatment of epithelial cells
Epithelial cells (described above) were detached as described in 2.1.1-2, centrifuged
at 400rcf for 10 minutes, resuspended and plated out in a 24-well plate at 1x105
cells/ml and left to incubate at 5% CO2, 37oC. When cells had reached pre-
confluence (70-80%), culture supernatants were removed and replaced with fresh
medium in the presence, absence or with a combination of human recombinant
cytokines. Table 2-1 shows the cytokine concentrations that were used for titration
experiments. In some combinations TNF-α, IL-4 or IL-13 were added at 100ng/ml as 
according to Kato et al, 2007. Epithelial cells were also treated with Phorbol 12-
myristate 13-acetate (PMA) (1ng/ml), poly I:C [50µg/ml] (both Sigma-Aldrich), IL-
1β [10ng/ml] (R&D Systems, Abingdon, UK) or a combination of TNF-α + IL-1β.
Cells were incubated for 6, 24, 48 or 72 hours, after which time the supernatants
were removed and centrifuged to remove cell debris. Cell-free supernatants were
frozen in aliquots at -70oC until ready for assay.
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Table 2-1 Titration of recombinant cytokines for the treatment of epithelial cells
Cytokine Concentration Cytokine Concentration
IFN-γ (PeproTech) 100U/ml TNF-α (PeproTech) 100U/ml
200U/ml 300U/ml
500U/ml 500U/ml
600U/ml 700U/ml
IL-4 (PeproTech) 25U/ml IL-13 (R&D Systems) 5U/ml
50U/ml 10U/ml
100U/ml 20U/ml
150U/ml 30U/ml
2.4 Pre-treatment of epithelial cells for IL-17RA blocking
experiments
Epithelial cells (2.1.1) were detached as previously described in 2.1.1, centrifuged at
400rcf for 10 minutes, resuspended and plated out in triplicate into a 24-well plate
(Nunc) at 1x105 cells/ml and incubated at 5% CO2, 37oC. When cells had reached
pre-confluence (70-80%), supernatants were removed and replaced with fresh
medium and cells were treated with either PMA [1ng/ml], TNF-α [25ng/ml] 
(Peprotech) in combination with IL-1β [10ng/ml] (R&D Systems), rIL-17A [5ng/ml] 
(R&D Systems), zymosan [20µg/ml] (InVivogen, Nottingham, UK), poly I:C
[50µg/ml] (Sigma-Aldrich) or LPS [5µg/ml] (Sigma-Aldrich), the latter three
indicating agonists for TLRs 2, 3 and 4, respectively. Some wells were also left
unstimulated.
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Cells were incubated for 6, 24 and 48 hours, after which time the supernatants were
removed and centrifuged to remove cell debris. Cell-free supernatants were frozen in
aliquots at -70oC until ready for assay. Cells remaining in the wells were detached
and stained for various markers and receptor expression.
2.5 IL-17RA receptor blocking
2.5.1 IL-17RA neutralisation titration
Before the neutralisation study was conducted, the neutralising IL-17RA antibody
was first titrated onto the cells in order to see which concentration of the antibody
had the ability to downregulate IL-17RA expression. Conjunctival epithelial cells
that had been grown until pre-confluence had their medium removed and were
washed twice with PBS before incubation with anti-IL-17RA at a concentration of
0.1, 0.5 and 1μg/ml for 2 hours. Some wells were left untreated. After this time, the 
cells were washed, trypsinized and transferred to micro-centrifuge tubes so that they
can be stained for expression of IL-17RA and analysed by flow cytometry.
2.5.2 IL-17RA neutralisation
Epithelial cells were set up in parallel and treated as in 2.4. Cells were then incubated
for 24 hours after which time cell-free supernatants were prepared and stored frozen
until further use. After washing, the cells were given fresh medium. To one of the
plates cells were treated with normal goat anti-IgG [0.5μg/ml] (R&D Systems), to 
another plate the cells were treated with goat anti-human IL-17RA antibody
[0.5μg/ml] (R&D Systems) and incubated for 2 hours. To a third plate, wells were 
replaced with fresh medium alone and incubated for 24 hours. After 2 hours, medium
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from the first two plates was removed and cells were washed twice. Fresh medium
was added to all wells and cells were stimulated with rIL-17A [5ng/ml] (as above),
including control cells that had not received any stimulation prior to treatment with
IgG or anti-IL-17RA antibody. The cells were incubated for 24 hours with
supernatants collected after this time and centrifuged to remove any cells and debris.
Supernatants were frozen in aliquots and stored until use in an assay.
2.5.3 CFSE labelling of PBMCs
Frozen peripheral blood mononuclear cells (PBMCs) isolated from leukocyte
depletions collected in cones (Blood transfusion service, UK) were thawed into
RPMI containing 10% FCS and spun at 400rcf for 10 minutes. Cells were washed in
RPMI and spun for a further 10 minutes then resuspended in 100µl RPMI containing
5µM carboxyfluorescein diacetate succinimidyl ester (CFSE) and incubated for 10
minutes at 37oC. After this 1ml RPMI-10% FCS was added to stop CFSE ad spun at
4000rpm for 4 minutes, after which cells were resuspended in the same volume of
medium and incubated for 30 minutes at room temperature. Cells were then spun at
400rcf and resuspended at a concentration of 1x106/ml in RPMI supplemented with
10% FCS (BIosera), non-essential amino acids, sodium pyruvate (2mM for both;
Invitrogen), 2x10-5 mercaptoethanol (Sigma) and 50µg/ml gentamycin (Invitrogen)
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2.5.4 Determining inhibition of lymphocyte proliferation
PBMCs labelled as in section 2.5.3 were plated out in a 96 well plate at 1x106
cells/well in triplicate. Three wells were left unstimulated and three wells were
stimulated with anti-CD3 (50ng/ml) and anti-CD28 (1µg/ml; BD Biosciences,
Oxford, UK). The remaining wells were supplemented with supernatants collected in
section 2.5.2 to make up a concentration of 5, 10 or 20% and also stimulated with
anti-CD3/CD28. Cells were incubated for 5 days at 37oC, 5% CO2.
2.6 CBMC and epithelial cell interaction
2.6.1 CBMC sensitisation
In order to mimic the actions of allergens in stimulating mast cells, CBMCs must
first be sensitised by treatment with IgE to upregulate their IgE receptors, before
stimulation with anti-IgE, which acts by cross-linking two IgE molecules thus
mimicking an allergen. The IgE used to sensitise the cells was dialysed before use to
remove the sodium azide. To achieve this, 100μl IgE (Abd Serotec, Oxford, UK) was 
added to a dialysis unit (Dialysis unit, 3.5kDa; Thermo Scientific, Pierce;
Leicestershire, UK), placed in a buoy and transferred to a beaker containing 2 litres
PBS and left on a magnetic stirrer for at least 2 hours. As sodium azide is 65 daltons,
IgE was retained within the dialysis tubing as the azide diffused out. CBMCs were
plated out at 1x106 cells/ml in 24 well plates and presensitised by adding IgE Ab
[4μg/ml] for 24 hours. 
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2.6.2 CBMC, epithelial cell co-culture
Conjunctival epithelial cells plated out at 1x105 cells/ml were grown until pre-
confluence and stimulated for 4 hours with IL-17, TNF-α + IL-1β, poly I:C and poly 
I:C + TNF-α + IL-1β. In parallel, presensitised CBMCs that had been seeded onto 24 
well plates at 1x106 cells/ml were left untreated or stimulated with anti-IgE
[25μg/ml] (Sigma-Aldrich), IL-17, TNF-α + IL-1β, PMA or poly I:C for 2 hours (at 
the concentrations indicated in section 2.4). CBMCs were harvested after this time
and spun at 4000rpm for 4 minutes. The cell pellet was resuspended in 1ml mast cell
culture medium and cultured with the appropriately stimulated epithelial cells.
Supernatants were collected at 24 and 48 hours and stored at -70oC. ELISAs were
used to quantitate the production of chemokines.
2.7 Cytokine secretion by ELISA
Supernatants collected as described (2.3, 2.4, 2.5.2 and 2.6.2) were used to detect and
quantify the level of various secreted proteins using commercially available ELISA
kits. The ELISAs were performed according to the manufacturers’ instructions.
Briefly, a 96-well Immunolon microplate (Nunc, Leicestershire, UK) was coated
with capture antibody (refer to Table 2.7) and incubated overnight at room
temperature.
Medium was aspirated and wells washed 3 times with wash buffer [0.05% Tween®
20 (Sigma-Aldrich) in phosphate buffered saline (PBS; Sigma-Aldrich)] after which
plates were blocked by the addition of Reagent Diluent [1% bovine serum albumin
(BSA; Sigma-Aldrich) in PBS] and incubated at room temperature for a minimum of
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1 hour. Wells were again washed 3 times after which samples or standards were
added to each well and incubated for 2 hours at room temperature. Standards were
prepared using recombinant human proteins of the targets of interest. A seven point
standard curve was made using a 2-fold serial dilution in duplicate wells in Reagent
Diluent, with the highest standard of 2000pg/ml for IL-8, IL-25, MMP3, MMP9 and
CXCL10; 1000pg/ml for IL-17, CCL17 and CCL20 and 20,000pg/ml for IL-17F.
After this time wells were aspirated, washed and the detection antibody (refer to
Table 2-2) added for 2 hours at room temperature. Wells were again aspirated,
washed and Streptavidin-horseradish peroxidase (HRP) was added to each well and
incubated for 20 minutes at room temperature. After this time the aspiration/washing
step was repeated and substrate solution was added to each well and incubated at
room temperature for 20 minutes, after which time Stop Solution (2N H2SO4) was
then added to each well. Plates were read at 450nm (405nm for IL-25) and the
concentration of protein in the samples determined from a standard curve by taking
the mean of each duplicate standard and plotting the absorbance against their known
concentration. From the standard curve a best-fitting curve was generated allowing
the concentrations of each sample under test to be calculated.
For the detection of sCD44 an ELISA kit (Bender MedSystems, Vienna, Austria)
was used according to manufacturer’s instructions. A plate pre-coated with the
capture antibody was provided and the assay carried out as indicated above from the
addition of the standards and samples.
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Table 2-2 Proteins of interest targeted for detection by ELISA
Protein Capture Antibody Detection Antibody Source
TSLP 0.8μg/ml 400ng/ml R&D Systems 
IL-8 4μg/ml 20ng/ml R&D Systems 
IL-17A 4μg/ml 150ng/ml R&D Systems 
IL-17F 0.8μg/ml 100ng/ml R&D Systems 
IL-25 1μg/ml 0.25μg/ml PeproTech 
MMP3 0.8μg/ml 200ng/ml R&D Systems 
MMP9 1μg/ml 200ng/ml R&D Systems 
sCD44 According tomanufacturer
According to
manufacturer Bender MedSystems
CXCL10 2μg/ml 50ng/ml R&D Systems 
CCL17 2μg/ml 100ng/ml R&D Systems 
CCL20 2μg/ml 50ng/ml R&D Systems 
2.8 Detection of MMP secretion by antibody array
Another approach used to identify the presence of MMPs in culture supernatants was
an antibody array (RayBiotech, Inc, Cambridgeshire, UK), that is capable of
detecting a number of proteins simultaneously (Table 2-3), but only semi-
quantitatively, hence providing a significant advantage over the more traditional
method used for detecting MMPs (Zhou et al, 2005). This assay was carried out at
room temperature according to manufacturer’s instructions, using reagents that were
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supplied. Membranes coated with antibodies were each placed in an 8 well plate and
blocked with 2ml 1x Blocking Buffer for 30 minutes at room temperature. After this
time, the blocking buffer was decanted and membranes were incubated with 1ml
supernatant from control and stimulated wells at room temperature for 2 hours.
Supernatants were decanted from the plate and each well was washed 3 times (5
minutes per wash) with 2ml of 1x Wash Buffer I on an orbital shaker. Membranes
were again washed twice allowing 5 minutes per wash with 2ml of 1x Wash Buffer II
with shaking. To the membranes, 1ml of diluted biotin-conjugated antibodies was
added and incubated for 2 hours. The same washing steps were carried out before the
addition of 2ml diluted HRP-conjugated streptavidin. Membranes were incubated at
4oC overnight after which they were washed as before.
In order to detect the reaction, excess wash buffer was drained and each membrane
was placed (protein side up) on a clean plastic sheet. Each membrane was then
covered with a 500μl solution of detection buffer (made from a 1:1 mixture of two 
separate detection buffers) and incubated at room temperature for 2 minutes. Excess
detection reagent was drained from the membranes and placed, protein side up, on
another plastic sheet. A second sheet was placed on the membranes and any air
bubbles gently smoothed away. The membrane array was exposed to x-ray film
(Super RX Fuji Medical x-ray film) for up to 40 seconds and the signal detected
using film developer. The signal intensities were quantified by densitometry (Kodak
digital science 1D 2.0 software) and the positive control was used to normalise the
results.
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Table 2-3 Position of specific antibodies on the membrane, to the proteins of
interest
2.9 Detecting cytokine secretion by Multiplex cytokine bead arrays
Culture supernatants were simultaneously investigated for the presence of IL-8 as a
positive control for epithelial cell responses, IL-10, IL-13 and TGF-β1 by a multi-
cytokine bead assay kit (Bender MedSystems), and carried out according to the
manufacturers’ instructions. TGF-β1 is secreted in a latent form, and therefore had to 
undergo acidification in order for the total amount of TGF-β1 to be detected in this 
assay. First, 20μl supernatant was diluted with 180μl assay buffer. To this 20μl 1N 
HCl (supplied in kit) was added to acidify the TGF-β1 and incubated at room 
temperature for 1 hour. After this time 20μl 1N NaOH (supplied in kit) was added to 
stop the reaction. Samples were then ready for assay.
Wells from a 96-well plate (multiscreen filtration plate; Millipore, Co Durham, UK)
were pre-wet with 50µl assay buffer then aspirated using a vacuum manifold.
Standards were prepared for each cytokine by setting up a 7 point serial dilution from
10000pg/ml to 14pg/ml and adding 25µl each to duplicate wells using the buffer as a
blank. To the remaining wells 25µl of sample supernatants were added in duplicate
A B C D E F G H
1 POS POS NEG NEG MMP-1 MMP-2 MMP-3 MMP-8
2 POS POS NEG NEG MMP-1 MMP-2 MMP-3 MMP-8
3 MMP-9 MMP-10 MMP-13 TIMP-1 TIMP-2 TIMP-4 NEG POS
4 MMP-9 MMP-10 MMP-13 TIMP-1 TIMP-2 TIMP-4 NEG POS
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and 25µl bead mixture and 50µl biotin-conjugate mixture consisting of beads
specific for TGF-β1 IL-8, IL-10 or IL-13 were added to all wells. Plates were 
covered and left to incubate on the orbital shaker at room temperature for 2 hours.
After this time the wells were aspirated using vacuum filtration and washed twice
with assay buffer. To each well 100µl assay buffer and 50µl streptavidin-PE solution
was added and incubated for 1 hour at room temperature. After washing, any
remaining liquid was removed by blotting on absorbent paper and 200µl assay buffer
added to each well, mixed and then transferred to 5ml polystyrene tubes for analysis
by flow cytometry.
The flow cytometer was set up using 2 sets of beads of differing sizes (4.4µm and
5.5µm), the bead populations being differentiated by varying intensities of an
internal fluorescent dye, detected in the FL-3- channel. Streptavidin binding to the
biotin conjugate was detected in the FL-2 channel therefore allowing the
quantification of the analytes. Data was analysed using Flow Cytomix Pro 2.2
software (Bender MedSystems).
2.10 Immunofluorescence and Flow Cytometry
Cells in suspension were transferred to 1.5ml microfuge tubes for one or two
parameter staining. The cell suspensions were first centrifuged in a microcentrifuge
for 4 minutes at 4000rpm, the supernatant was removed and cells resuspended in
PBS and washed again. Cells were then stained using directly conjugated antibodies
(direct immunofluoresence) or with unconjugated antibodies (indirect
immunofluorescence) with appropriate controls included as indicated in table 2-4).
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To the pellet, antibodies were added at the appropriate volume or concentration and
incubated at 4oC for 30 minutes. After this time, cells were washed 3 times with PBS
and finally resuspended in PBS and transferred to 5ml polystyrene tubes. For indirect
immunofluorescence staining, a secondary antibody was added, anti-goat FITC
(fluorescein isothiocyanate) [1μg/ml] (Southern Biotech, Cambridge, UK) and cells 
incubated for 30 minutes at 4oC. The cells were washed and the pellet resuspended in
PBS. Analysis was carried out by flow cytometry (FACScalibur; BD Biosciences),
plotting forward scatter (FSC) vs. side scatter (SSC) to locate the live cell region then
acquiring 10,000 events in the live region. The data was analysed using Winlist
(Verity Software House Inc, Maine, USA). A region indicating the live cell
population was drawn and from this a histogram was created looking at the cells in
the FL1 channel for FITC or CFSE, FL2 channel for PE (Phycoerythrin) and FL4
channel for APC (Allophycocyanin). The mean fluorescence intensity or percentage
expression was measured. To analyse proliferation, a gate was drawn around
lymphocytes and lymphoblasts (proliferating cells) and the percent of proliferation
was determined based on diminishing fluorescent intensity.
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Table 2-4 List of antibodies used for immunofluorescence staining for flow
cytometry
Primary Antibody Raised In Source Volume /concentration
IgG control FITC Mouse BD Biosciences 5μl 
IgG control PE Mouse BD Biosciences 5μl 
IgG control APC  Mouse BD Biosciences 5μl 
CD54 (clone HA58) APC  Mouse BD Biosciences 5μl 
IL-17RD PE  Mouse R&D Systems 5μl 
c-Kit (clone 104D2) FITC  Mouse Abcam 5μl 
FcεRI (clone AER-37) PE    eBioscience 10μl 
IL-17RA  Goat R&D Systems 0.5μg/ml 
IL-17RC  Goat R&D Systems 0.5μg/ml 
2.11 Donors
2.11.1 Biopsy specimens
All specimens used in this study were obtained from our collection of banked tissues
in the laboratory. All procedures (2.11.1 and 2.11.2) were approved by the local
Ethics Committee and informed consent was obtained from all subjects.
Conjunctival biopsies from 31 subjects attending clinics at Moorfields Eye Hospital
were obtained, taken from one eye per donor. Biopsies were taken from the upper
tarsal (AKC, VKC, normal controls) or bulbar conjunctiva (ocular ciccatricial
phemphigoid [OCP], SAC). The control specimens (n=6; 69.0±19.9 years, three
female) were from patients undergoing elective surgery. SAC subjects were biopsied
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after 8 hours post conjunctival allergen challenge using grass pollen extract (n=6; 18-
65 years, all male). CAED subjects all had active disease: VKC (n=6; 24.0±2.6
years, two male); AKC (n=6; 37.8±21.7 years, two male). Treatment in all cases had
been stopped at least 4 weeks (for corticosteroid) or 7 days (sodium cromoglycate
treatment) prior to biopsying. Of the OCP patients, those that were active (n=5;
70.2±16.0 years, 2 male) had acute inflammation whilst those that had chronic
disease (n=5; 72.6±10.5 years, 1 male) did not have clinically apparent inflammation.
None of the OCP patients were receiving anti-inflammatory therapy at the time of
biopsying. The diagnosis of disease was made clinically and by direct
immunofluorescence of the conjunctiva for OCP.
2.11.2 Ocular swab samples
A total of 58 subjects with either active or controlled disease were recruited, this
included; AKC (n=7; 34.3±3.2 years, 5 male), OCP (n=35; 70.8±2 years, 19 male)
and normal controls (n=16; 69.2±2.1 years, 8 males). The right conjunctiva was used
in all cases and was anaesthetised with preservative-free proxymetacaine 0.5% eye
drops (Minims™; Chauvin Pharmaceuticals, Kingston-Upon-Thames, UK). The
upper eye lid was inverted and a swab (Dacron polyester-tipped swab; Hardwood
Products Co LP, Maine, USA) was gently brushed along the tarsal conjunctiva and
immediately placed in a tube containing 200μl RNAlater® (Ambion Inc, Texas,
USA). Samples were stored at 4oC then transferred to a -20oC freezer. All procedures
(2.11.1 and 2.11.2) were approved by the local Ethics Committee and informed
consent was obtained from all subjects.
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2.12 Immunohistochemistry
Previously obtained conjunctival biopsy tissue sections (2µm thick, stored at -70oC)
as described (Hingorani et al, 1998) were obtained from our tissue bank, from
subjects with AKC and VKC (CAED) as well as individuals with SAC and those
without any inflammatory eye disorder (non-inflamed controls). Sections were
allowed to thaw; each section or slide containing mast cell cytospins were ringed
with a wax pen (Dako, Cambridge, UK) and blocked with peroxidase (3%) (Dako)
for 10 minutes at room temperature. Slides were then washed 3 times for 5 minutes
with PBS. Sections were blocked with 10% normal rabbit serum (Dako) at room
temperature for 30 minutes. The slides were drained and negative control antibody
(diluted to the same protein concentration as primary antibody) or appropriately
titrated primary antibody of interest (Table 2-5) was added and incubated overnight
at room temperature in a humidified chamber.
The slides were washed 3 times for 5 minutes in PBS and incubated at room
temperature for 2 hours with a secondary biotinylated antibody (Table 2-6). After
washing, streptavidin-horseradish peroxidase (1:200) was added for a further 2 hours
followed by washing. A substrate was then applied and left for 25 minutes; using
3,3’-diaminobenzidine tetrahydrochloride (DAB), which stains brown. The slides
were then washed under running tap water for 5 minutes. Mayer’s haematoxylin
(Dako) was applied to sections for 2-3 minutes then washed under tap water for 5
minutes; slides were drained then mounted with glycergel mounting medium (Dako)
and covered with a coverslip. For sections that were double-stained, one of the
molecules of interest was stained first and then the procedure repeated again for the
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second molecule using a different substrate, 3-amino-9-ethylcarbazole (AEC), which
gives a pink colour, before slides were mounted.
2.12.1 Quantification of immunohistochemical staining
In order to quantify the staining of the tissue sections, sections were scored as the
total number of positively stained cells, or for expression intensity in the epithelium
and stroma. The scoring system was graded on a scale of 0-3, with 0 meaning no
staining, up to 3 meaning very intense staining.
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Table 2-5 Primary antibodies and substrates used for detection in
immunohistochemistry
Primary Antibody Raised In Source Dilution Substrate
IgG control Mouse Santa cruz 1:100
IgG control Rabbit Dako 1:100
IgG control Goat R&D Systems 1:100
TSLP Rabbit Santa cruz 1:250 DAB
IL-13 Rabbit Santa cruz 1:100 AEC
CD3 Mouse Dako 1:10 DAB
IL-17 Rabbit Santa cruz 1:100 DAB
CD4 Mouse Dako 1:10 AEC
IL-17RA Goat R&D Systems 1:25 DAB
IL-17RC Goat R&D Systems 1:25 DAB
Chymase Mouse Abd Serotec 1:100 AEC
Tryptase Mouse Abd Serotec 1:100 AEC
Table 2-6 Secondary antibodies used for immunohistochemistry
Secondary Antibody Raised In Source Dilution
IgG F(ab’)2 Rabbit Dako 1:200
IgG F(ab’)2 Goat Dako 1:200
IgG F(ab) Donkey Abcam 1:100
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2.13 Quantification of mRNA from conjunctival epithelial cells
2.13.1 RNA extraction from conjunctival epithelial cells
IOBA cells were detached from flasks using trypsin, centrifuged at 400rcf for 10
minutes, resuspended in culture medium then seeded onto 24 well plates at a density
of 1x105 cells per well. Confluent cells were treated with TNF-α [25ng/ml] ± IL-1β 
[10ng/ml], IL-4 [20ng/ml] or IL-13 [20ng/ml], IL-17 [10ng/ml], zymosan [20μg/ml], 
poly I:C [50μg/ml] ± TNF-α + IL-1β and LPS [5μg/ml] for 1, 4 and 6 hours. Cells 
that had reached 70-80% confluence were treated for 24 hours.
For total RNA isolation, the procedure was carried out using RNeasy® Mini kit
(Qiagen, Crawley, UK) according to the manufacturers’ instructions. Epithelial cells
were lysed using a buffer supplied in the kit and the lysate was then homogenised by
centrifugation (QIAshredder spin column, Qiagen). The remaining procedure was
carried out using RNeasy spin columns according to manufacturer’s instructions.
RNA was eluted by the addition of 30μl RNase-free water to the spin column and 
centrifugation for 1 minute at 8000rcf into a 1.5ml collection tube. The concentration
of RNA was measured by spectrophotometry (NanoDrop®; Thermo Scientific) and
the purity analysed by taking the ratio of readings at 260nm and 280nm (A260/A280).
RNA was either stored immediately at -70oC or reverse transcribed.
2.13.2 RNA extraction from conjunctival swabs
RNA was extracted using the same procedure detailed in section 2.12.1 with the
exception of a slight modification. Swabs were thawed on ice then removed from
their tube containing RNA stabiliser. Using cocktail sticks, the swabs were
Chapter 2 Methods & Materials
Page 67
transferred to a new tube containing the buffer supplied in the kit and vortexed. The
lysate was then homogenised as previously described.
2.13.3 RNA transcription
Template RNA isolated as in 2.12.1and 2.12.2 was converted to cDNA by reverse
transcription (QuantiTect® or Omniscript® reverse transription kit, Qiagen). All
reactions were prepared on ice, the first step involved the elimination of genomic
DNA using 0.5µg template RNA and a buffer supplied for the removal of genomic
DNA. Samples were incubated at 42oC for 2 minutes then placed on ice. A reverse-
transcription master mix was made up using the reagents supplied, this included
reverse transcriptase, a buffer and a primer mix containing Mg2+ and dNTPs. This
master mix was added to each template RNA sample from the first step and
incubated for 15 minutes at 42oC. Reverse transcriptase in the reaction was
inactivated by incubating at 95oC for 3 minutes. Samples were stored at -20oC until
RT-PCR was carried out.
2.13.4 Real-time quantitative PCR of conjunctival epithelial cells
To quantify the relative amount of mRNA, 20x TaqMan gene expression assays were
used which contain primer and probes (inventoried stock; refer to table 2.13). The
assay includes the use of 2x TaqMan Gene Expression Master Mix which contains
Ampli Taq Gold® DNA polymerase, Uracil-DNA Glycosylase and dTNPs with
dUTP (Applied Biosystems, Warrington, UK). Each was mixed with cDNA and
made up with RNase-free water to set up a 20µl reaction in a 96 well reaction plate
(Applied Biosystems). Reactions were run in triplicate using a thermal cycler
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(7900HT Fast Real-Time PCR System, Applied Biosystems) and analysed with SDS
2.2.2 software.
The following conditions were used for the cycling protocol; (1) Initial activation of
DNA polymerase for 10 minutes at 95oC; (2) denaturation for 15 seconds at 95oC;
(3) combined annealing and extension step for 1 minute at 60oC with fluorescence
data collection. Steps 2 to 3 were repeated for a total of 40 cycles. Cycle threshold
(Ct) values were recorded and data was normalised by running each sample with
Beta Actin as a housekeeping gene with the fold change in gene expression
calculated using the 2-∆∆Ct method:
∆Ct = Ct target gene - Ct housekeeping gene
  ∆∆Ct = ∆Ct sample - ∆Ct unstimulated
Fold change = 2-∆∆Ct
2.13.5 Real-time quantitative PCR of conjunctival swabs
Quantification of mRNA from samples taken from conjunctival swabs was carried
out by multiplex PCR. A four plex reaction mix was prepared with 2x QuantiTect
Multiplex PCR kit (Qiagen), containing HotStarTaq DNA polymerase, QuantiTect
Multiplex PCR buffer, dNTP mix including dUTP and 11nM MgCl2. This was mixed
in PCR tubes with cDNA, 10x forward and reverse primers (table 2-7) and sequence
specific probes for all target genes. Reactions were set up with hypoxanthine
phosphoribosyl transferase 1 (HPRT1) as the housekeeping gene with the following
cycling conditions; (1) Initial activation of HotStatTaq for 15 minutes at 95oC; (2)
Denaturation for 60 seconds at 94oC; (3) Annealing and extension step for 60
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seconds at 60oC with 50 repeated cycles of steps 2 to 3 (Rotorgene 3000; Corbett).
By taking the ratio of each target gene with HPRT1, mRNA was quantified using the
∆∆Ct method.
Table 2-7 Genes of interest and their target sequences
Gene Assay ID / Part number / Target Sequence Source
TSLP Hs00263639_m1 AppliedBiosystems
IL-8 Hs99999034_ml AppliedBiosystems
IL-13 Hs99999038_m1 AppliedBiosystems
IL-25 Hs03044841_m1 AppliedBiosystems
Actin 4352935E AppliedBiosystems
IL-17A
Forward - CCAAATTCTGAGGACAAGAACTTCC
Reverse - CAAGGTGAGGTGGATCGGTTG
Sigma-Genosys
Ltd.
TLR2
GGGTCATCATCAGCCTCTCC
CCTGAGGGAATGGAGTTTAAAGATC
Sigma-Genosys
Ltd.
TLR4
CAAATGCCCCTACTCAATCTCTC
AAACTATCAAAATTATTTCTTAAAGTCAGC
Sigma-Genosys
Ltd.
TLR9
GCAATGTCACCAGCCTTTCC
GCAGTTCCACTTGAGGTTGAG
Sigma-Genosys
Ltd.
IL-13
CCCTTGCCAGACATGTGGTG
TCCCCAACGGTGACAAACAC
Sigma-Genosys
Ltd.
HPRT1
TATGGACAGGACTGAACGTCTTG
GATCTATCACTATTTCTATTCAGTGCTTTG
Sigma-Genosys
Ltd.
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TLR mediated immunity at the ocular surface mucosa
3.1 Introduction
The location of the eye presents the ocular surface with the means to interface with
the external environment. The ocular mucosa is continually exposed to airborne
particles such as dust, pollen and microbes. As well as functioning as a barrier to
such contact, the mucosa also takes part in host defence by responding to invading
pathogens. The conjunctival epithelium forms part of the ocular mucosa and is at the
forefront of the innate immune response owing to its array of surface receptors,
namely TLRs and production of cytokines and chemokines. As a result, TLRs of the
epithelium are essential in recognising microbial structures and initiating an immune
response. Problems may arise however when the immune response becomes
exaggerated and uncontrolled, thereby exacerbating any ongoing inflammation.
It has been proposed that there is a correlation between TLRs and allergic disease
(Bauer et al, 2007), and this association has also been highlighted in allergic
conjunctivitis. One such study has demonstrated that subjects with VKC had
increased TLR4 and decreased TLR2 compared to normal subjects (Bonini et al,
2005), whilst Cook et al observed increased TLR2 from the conjunctiva of AKC
patients (Cook et al, 2006). As part of their role in the innate inflammatory response,
agonists to TLRs1-4 have been shown to induce the upregulation of the
proinflammatory cytokines, IL-6 and IL-8, in primary human conjunctival epithelial
cells (Li et al, 2007; Chung et al, 2009). Moreover, upon activation of TLR2, 3 and 4
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salivary epithelial cells upregulate their expression of CD54, CD40 and MHC class I
molecules (Spachidou et al, 2007).
As part of their role in orchestrating the innate immune response, earlier studies have
revealed that the conjunctival epithelium from chronic allergic tissues express
ICAM-1 and HLA-DR to a greater extent than milder allergic eye disorders
(Hingorani et al, 1998). Certain proinflammatory cytokines have also been detected
in normal tissues, but more recently in vitro experiments have shown that upon
stimulation, conjunctival epithelial cells upregulate the secretion of various cytokines
and chemokines, such as IL-6, IL-8 and RANTES, that may influence the outcome of
the inflammatory response (Hingorani et al, 1998; Enrίquez-de-Salamanca et al,
2008).
The varying characteristics that distinguish the conjunctival epithelium have allowed
researchers to speculate the contribution they make to not only innate immunity but
the acquired immune response. By triggering an immune response through TLR
signalling, the epithelium is poised to secrete products that will lead to the
recruitment of inflammatory cells to areas of invasion. As part of the innate response,
it would be important to establish TLR expression on conjunctival epithelial cells,
which will be the focus of this chapter.
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3.2 Expression of TLR2, TLR4 and TLR9 at the ocular surface
The expression of certain molecules on the conjunctiva allows the epithelium to
respond, hence giving innate protection against invasion from foreign particulates.
Unfortunately, with some chronic ocular inflammatory disorders there is a need to
treat patients with immunosuppressive drugs such as steroids. Problems arise when
patients become immunocomprimised and are therefore subject to secondary
infections, which may be bacterial, fungal, viral or parasitic in origin. In such a case,
there may be an increase in TLRs in response to this infection from subjects
suffering from ocular inflammatory disorders. To address this we looked at the
mRNA expression levels in freshly isolated conjunctival swab specimens of certain
TLRs, the expression of which has been shown to be altered during disease.
There was basal expression of TLR2, TLR4 and TLR9 detected at low levels in
normal conjunctival swabs. For both TLR2 and TLR4, expression in OCP and AKC
conjunctival swabs appeared to be greater than that of normal controls. When
compared with AKC, expression levels in OCP were also greater, though there was
not a significant difference between the groups (Figure 3-1A and B). In contrast, the
expression of TLR9 was slightly increased in AKC compared with normal and OCP
samples, again this did not reach significance (Figure 3-1C). Taking into account the
ratio between each gene and HPRT1, the level of expression of TLR2 and TLR4
between all three groups is greater than TLR9 expression. In this study it appears that
there is no association between the level of TLR expression and ocular inflammation
at the conjunctiva.
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Figure 3-1 TLR mRNA expression remains unaltered in normal and inflamed
conjunctiva. Conjunctival swabs taken from normal (n = 16), OCP (n = 35) and
AKC (n = 7) subjects were used to isolate RNA. The expression of mRNA for TLR2
(A), TLR4 (B) and TLR9 (C) was assessed by real-time RT-PCR. Each symbol
represents an individual and lines indicate the mean expression, statistical analysis
was carried out using 2-tailed Mann Whitney U test.
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3.3 Effect of microbial peptide exposure on conjunctival epithelial
cells
To further investigate the role of TLRs in innate immunity at the ocular surface, it is
important to determine whether the cells found at the conjunctiva have the ability to
elicit an inflammatory response to microbial antigens. During inflammation, there is
usually an influx of cells such as neutrophils, attracted to the site via the secretion of
chemokines such as IL-8. Cell migration and adhesion to inflammatory sites are also
directed by CD54 and CD44.
A conjunctival epithelial cell line was cultured in the presence of zymosan, poly I:C
or LPS, ligands to TLR2, TLR3 or TLR4 respectively, and the response examined by
looking at their secretion and expression of activation markers (sCD44, IL-8 and
CD54) by ELISA and flow cytometry (Figure 3-2). The production of sCD44 was
significantly increased in response to exposure to zymosan (p<0.05) and poly I:C
(p<0.01) in comparison to untreated cells. Treatment with LPS did not result in a
significant difference in sCD44 expression above that of unstimulated cells (Figure
3-2A). To further confirm whether the cells were indeed activated, IL-8 secretion
was also quantitated. Unlike sCD44, exposure to poly I:C only resulted in a
significant increase in IL-8 (p<0.01; Figure 3-2B). The expression of CD54 was very
high in unstimulated cells and therefore the mean fluorescent intensity (MFI) was
used to represent CD54 expression by epithelial cells (Figure 3-2C). Again, it was
only upon treatment with poly I:C that significant expression of CD54 was observed
(p<0.01) compared to unstimulated cells (Figure 3-2D). This suggests that the cells
can be activated by at least two of the three TLR ligands used in this study.
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Figure 3-2 Conjunctival epithelial cells respond to certain fungal and viral
ligands. IOBA-NHC epithelial cells were stimulated for 24 hours with zymosan,
poly I:C and LPS after which, culture supernatants were collected for sCD44 (A)
and IL-8 (B) production by ELISA. Cells were also harvested and stained for their
expression of CD54 (C) and acquired by flow cytometry; where: - - - represents IgG
control, — represents unstimulated cells and — represents poly I:C stimulated cells.
Due to the high level of CD54 expression by unstimulated cells, the mean
fluorescent intensity was used to show the level of CD54 expression (D). Results
were analysed by taking a comparison between treated and untreated cells, * p<0.05;
** p<0.01.
ng
/m
l(
m
ea
n

S
E
M
)
unstimulated zymosan poly I:C LPS
0
1
2
3
*
**
A
pg
/m
l(
m
ea
n

SE
M
)
unstimulated zymosan poly I:C LPS
0
100
200
400
500
600 ** B
M
FI
(m
ea
n

SE
M
)
unstimulated zymosan poly I:C LPS
0
70
140
160
170
180
**
D
10 1 10 2 10 3 10 4
CD54 PE
0
10
0
20
0
30
0
40
0
50
0
N
um
be
r
C
Chapter 3 Results
Page 76
3.4 Effect of allergens on conjunctival epithelial cells
In addition to pathogens, allergens can induce inflammatory responses to some
degree at the ocular surface during SAC but not chronic inflammation as seen in
disorders such as AKC and OCP. In SAC there is usually infiltration of mast cells,
eosinophils and neutrophils. We therefore hypothesised that conjunctival epithelial
cells would have the ability to be stimulated by allergens found in the environment
and initiate an inflammatory response. This was again monitored by their secretion of
sCD44 and IL-8 and their expression of CD54.
Treatment with the allergen peptides led to a significantly increased secretion of
sCD44 in cells exposed to D.farinae and D.pteronyssinus (p<0.01 for both) above
that of untreated cells, the greatest effect was detected in cells treated with Timothy
grass (p<0.01; Figure 3-3A). The level of IL-8 remained unaltered after 2 hours in
the presence of the peptides, at 6 and 24 hours IL-8 secretion increased in relation to
cells treated with the same peptide after 2 hours, this increase failed to reach
significance when compared to unstimulated cells (Figure 3-3B). Again the
expression of CD54 was already high in unstimulated cells and treatment with the 3
peptides failed to augment this expression (Figure 3-3C). This data implies that the
conjunctival epithelial cell line used in this study may be partly activated by
allergens; hence the increase in sCD44 but not IL-8 and CD54 compared to
unstimulated cells.
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Figure 3-3 Conjunctival epithelial cells respond to allergens. IOBA-NHC
epithelial cells were stimulated for 2, 6 and 24 hours with D.farinae,
D.pteronyssinus and Timothy grass and culture supernatants were collected for
sCD44 (A) and IL-8 (B) production by ELISA. Cells were also stained for their
expression of CD54 (C) and acquired by flow cytometry. Statistical analysis was
carried out using Student’s T test, taking a comparison between treated and
untreated cells, ** p<0.01.
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3.5 Discussion
The ability of the epithelium to recognise microbial pathogens and produce cytokines
that function to recruit other cells to the site of injury is crucial in immunity. This
data confirms the expression of TLRs 2, 4 and 9 in the conjunctiva, which is
necessary in recognising invading molecules. Epithelial cells of the conjunctiva also
respond to microbial challenge, demonstrated here by the TLR3 ligand (poly I:C)
induced increase in the secretion of IL-8 and upregulation of the adhesion molecule,
CD54. In contrast, the allergen peptides failed to augment cytokine secretion and
CD54 expression.
Earlier studies have indicated that allergic eye disease can augment the level of TLR
expression, demonstrated by an increase in TLR4 expression and decrease in TLR2
expression in VKC subjects (Bonini et al, 2005). Our data was unable to correlate the
expression of TLRs with disease, although we cannot draw the same conclusions as
the Bonini study as the tissues used in this study were from AKC subjects. Subjects
with VKC or AKC may be susceptible to different infections as they are mediated by
different cell types. This may be of relevance for example during infection by
intracellular pathogens. Such an infection can be diminished by IFN-γ present in Th1 
mediated disorders such as AKC. Conversely, subjects with VKC that have dominant
Th2 expression are afforded less immunity towards infection by intracellular
parasites. This may explain the differential expression of TLRs observed by the
authors. In contrast, another group has shown elevated levels of TLR2 from
impression cytology AKC specimens, the authors also highlighted the finding that
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IFN-γ and Staphylococcus aureus stimulated conjunctival epithelial cells as seen by
upregulated TLR2 (Cook et al, 2006). It is therefore conceivable that IFN-γ present 
in the micro-environment of subjects with AKC could trigger enhanced TLR2
expression; unfortunately our findings were unable to prove this. We are unable to
say whether these subjects exhibited secondary infections, and any steroids
administered at the time may have had an effect on TLR expression. From the OCP
and AKC tissue specimens that were investigated, it is clear that in each group there
were a few subjects that had all three TLRs upregulated above controls. It is
therefore possible that these subjects may have been suffering from an ongoing
infection. TLR expression is not exclusive to the conjunctival epithelium,
neutrophils, monocytes, dendritic cells and T cells have been shown to express a few
if not all TLRs (O’Mahony et al, 2008; Bonini et al, 2005). Our method of obtaining
samples was by the use of conjunctival swabs which will always result in a
heterogeneous population of cells; as a result we are unable to differentiate any
augmentation in TLR expression from epithelial cells only.
The expression of TLRs at the ocular surface has already been established, with
TLRs1-10 present at the mRNA level of the conjunctival epithelium (Lambiase et al,
2011). Many reports have examined the role of S. aureus on the inflammatory
response of human corneal or conjunctival epithelial cells. Notably, TLR2 becomes
activated and cells respond by inducing pro-inflammatory cytokine production (IL-6,
IL-8 and TNF-α) as well as CD54 (Li et al, 2008; Cook et al, 2005). The results from
this chapter reveal a disparate profile in cells treated with the TLR2 ligand, zymosan.
Other than upregulating sCD44 secretion, zymosan failed to alter IL-8 and CD54
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responses; this was also true for LPS. One hypothesis which may explain the lack of
response from zymosan and LPS may be due to two differing factors; the location of
the TLRs and a possible deficiency in MD2 expression. It has been demonstrated that
TLR2 and TLR4 are localised in the cytoplasm of human corneal epithelial cells and
not on the surface, as such the cells were unresponsive to LPS as they failed to
upregulate IL-6 and IL-8 (Ueta et al, 2005). Conversely the accessory molecule to
TLR4 – MD2, which is essential in LPS recognition, has very minimal expression if
at all in conjunctival epithelial cells. However, pre-treatment of these cells with IFN-
γ augmented MD2 expression thus allowing the cells to respond to LPS (Talreja et
al, 2005). In contrast to zymosan and LPS, the TLR3 ligand – poly I:C was a
powerful stimulant on epithelial cells in our study. Poly I:C is a synthetic dsRNA
analogue that mimics viruses, it has been implicated as an inducer of inflammatory
cytokines, namely IL-6 and IL-8 (Ueta et al, 2005). More recently it has been
described in human conjunctival epithelial cells as having the ability to upregulate
nearly 200 transcripts of cytokines, chemokines and molecules of the epithelial cell
surface, thereby indicating a role for TLR3 in regulating the allergic immune
response (Ueta et al, 2010). As we have demonstrated that TLR ligands, especially
poly I:C, are capable of activating conjunctival epithelial cells, they will be used
throughout the remaining study to monitor the cells response.
Another important mediator in allergic disorders is that of allergens which normally
induce a milder and more common form of allergic conjunctivitis such as that seen in
SAC and PAC, where mast cells predominate. There are many sources of allergens in
the environment, the most common of which in allergic conjunctivitis are thought to
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be two species of house dust mite, Dermatophagoides farinae and
Dermatophagoides pteronyssinus (Seto et al, 2009). Current literature has shown in
both human bronchial and conjunctival epithelial cells that both allergens stimulate
the induction of IL-8, IL-6 and GM-CSF cytokine release (King et al, 1998; Seto et
al, 2009). In our study we had the addition of a further allergen – Timothy grass, but
we were unable to reproduce such findings. As with the use of TLR2 and TLR4
ligands only sCD44 was modulated above that of unstimulated cells. Treatment with
grass produced a pronounced sCD44 response but failed to provoke a similar effect
in IL-8 secretion and CD54 expression, which may point towards divergent
signalling pathways utilised by receptors to the allergens. The mechanism in which
allergens can promote inflammation is usually through the production of proteases,
in the case of house dust mites this could take the form of serine or cysteine
proteases (Seto et al, 2009). Proteases activate protease-activated receptors (PARs),
in which PAR1 and PAR2 have been demonstrated to be expressed in human
conjunctival epithelial cells (Nickel et al, 2006). By stimulating the cells with PAR1
and PAR2 activators, which led to an increase in production of IL-6, the authors
illustrated that both receptors are functionally active (Nickel et al, 2006). Different
proteases activate different PARs, for example, thrombin activates PAR1 and trypsin
PAR2 (Nickel et al, 2006). As our conjunctival epithelial cells were routinely
passaged, it is possibly that before the addition of allergens to the culture, the
receptors were already activated. These actions may also have resulted in p38
phosphorylation as described in studies involving PAR2 activation by trypsin on oral
keratinocytes (Rohani et al, 2010). Their investigation also revealed that induction of
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innate immune responses via phosphatidylinositol 3 kinase (PI3K) signalling, may be
inhibitory to the actions of PAR1 and PAR2. Further interference with allergen
treatment in our study may have activated this signalling pathway and subsequently
dampened the cells response.
We have shown that the conjunctival epithelium does take part in innate immunity
through the actions of receptors on their surface and by their production of
inflammatory cytokines. By using a conjunctival epithelial cell line and culturing
them with antigens that are commonly found in our surroundings, we have
established a model that can be used to mimic the environment of the conjunctiva
during allergic conjunctivitis. Further investigations will explore how the epithelium
may be contributing to allergic disorders through their production of Th2 associated
cytokines.
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Cytokine micro-environment of conjunctival epithelial cells
during chronic allergic eye disease
4.1 Introduction
Of the many forms of allergic conjunctivitis that have been documented, specific
characteristics have been identified that can distinguish between the different types.
The main features that typify allergy at the ocular surface usually arise from the
inflammatory environment of the eye in the course of the conjunctivitis. During mild
ocular allergy such as SAC, mast cells are the predominant cell type. In such a
situation mast cells become activated leading to subsequent degranulation and
release of histamine, prostaglandins and leukotrienes (Trocme & Sra, 2002).
Although other cell types such as eosinophils and neutrophils have also been found
to be present in conjunctival tissues during SAC, they are not considered to take part
in driving this disorder (Anderson et al, 1997). As well as the different mediators that
are released by mast cells, they also secrete the Th2 cytokine IL-13 during the late
phase reaction (Trocme & Sra, 2002).
In ocular allergy such as SAC, there have not been any reports of the presence of T
cells in this disorder in contrast to chronic disorders affecting the eye such as AKC
and VKC which are dominated by T cells infilitrating the area. These subtypes of
allergic conjunctivitis are characterised by increased mRNA expression and
enhanced expression of IFN-γ in AKC tissues and IL-5 in VKC tissues (Metz et al,
1997; Calder et al, 1999). In addition to the T cell mediated effects seen in other
chronic diseases in addition to CAED, an epithelial-derived cytokine has been
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implicated in driving the allergic inflammatory response. TSLP is the cytokine in
question and it has been reported that activated, naïve CD4+ T cells are able to
produce high amounts of IL-5, IL-13 and TNF-α when primed by TSLP-activated 
DCs and Langerhans cells (Soumelis et al, 2002). In contrast it has also been
demonstrated that decreased levels of IL-10 and IFN-γ are seen under the same 
conditions (Ebner et al, 2007). Both of these observations suggest a role for TSLP in
CD4+ T cell differentiation into effector Th2 cells and subsequent Th2 mediated
allergic disease. Further evidence to support the role of TSLP in the pathogenesis of
allergic disease has shown an increase in the expression of this cytokine in the
lesional skin of individuals with inflammatory disorders as well as in asthmatic
airways (Soumelis et al, 2002; Ying et al, 2005).
With such compelling evidence it is tempting to speculate that, as well as the other
cytokines conjunctival epithelial cells are known to produce, as detailed in chapter 3,
they might also be capable of secreting T cell-associated cytokines. The ability to
demonstrate this characteristic will enable the conjunctival epithelium to be directly
involved in both the innate and adaptive arms of the immune response. This chapter
will aim to identify whether this may indeed be true and if it has any bearing on the
severity of allergic conjunctivitis.
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4.2 IL-13 is localised to the conjunctival epithelium in CAED
Evidence to date has shown that the expression of IL-13 in CAED, either from
mRNA expression, tear samples or T cells isolated from conjunctival biopsies, is
found to be increased above normal control subjects (Montan et al, 2002; Leonardi et
al, 2006; Calder et al, 1999). This has led to the belief that IL-13 may correlate with
severity of disease in CAED. So far the expression of IL-13 has not been shown in
conjunctival tissue specimens in both the mild and chronic ocular allergies. To study
the expression of IL-13 at the conjunctival surface, biopsy sections were used to
evaluate whether the expression of this cytokine is altered according to disease state.
4.2.1 IL-13 expression at the ocular surface
To investigate whether biopsies from CAED tissues express increased levels of IL-13
compared to normal controls, either expressed by conjunctival epithelial cells or by
CD3+ T cells, two colour immunohistochemical staining was used.
As a negative control, an AKC section was stained with a CD3 and IL-13 IgG
control antibody, a minimal level of background staining was picked up along the
epithelium (Figure 4-1A). Within SAC sections, goblet cells found in the epithelium
demonstrated significant IL-13 staining (Figure 4-1B). In CAED sections (AKC)
there was double staining of CD3 and IL-13 within the epithelium – localised to
those areas where there is darker brown/black staining, indicating the combination
of red and brown staining (Figure 4-1C). IL-13+ staining was also observed to be
scattered in the stroma (Figure 4-1C). In VKC tissues stained for IL-13 alone, the
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epithelium was also observed to have intense IL-13 along the epithelium (Figure 4-
1D&E).
The sections were graded to quantify the staining intensity of IL-13 staining between
the different ocular disorders and the controls. Within the epithelium, IL-13 staining
was intense in both CAED sections and GPC above that of the controls (p<0.05).
There was also increased IL-13 staining in SAC sections which was predominantly
found in the goblet cells within the epithelium (Figure 4-2A). Conversely, in the
stroma IL-13 staining was not detectable in the controls, SAC or GPC groups, and
the staining that was observed in VKC and AKC was weak and failed to reach
significance above controls (Figure 4-2B).
The level of IL-13 expression at the ocular surface was further characterised by
quantifying IL-13 mRNA in conjunctival swabs from normal, OCP and AKC
subjects. As demonstrated with the results from the immunohistochemical staining,
normal subjects had either very low expression of IL-13 mRNA or none at all. The
same was also found within the OCP group, although one individual had higher
levels of IL-13. There was a significantly greater expression of IL-13 in AKC
compared with normals (p<0.05) and OCP (p<0.01) (Figure 4-3).
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Figure 4-1 IL-13 is localised to the epithelium and stroma of conjunctival tissues.
Conjunctival biopsies were stained for the expression of CD3 (brown) and/or IL-13
(red) by immunohistochemistry; (A) AKC; n = 6 [CD3 and IL-13 IgG control], (B)
SAC; n = 3 [double stain, CD3 and IL-13], (C) AKC; n = 6 [double stain, CD3 and IL-
13], (D) VKC; n = 6 [IL-13], (E) VKC; n = 6 [IL-13] magnified insert of D. Arrows
indicate areas of positivity. Images were captured using Motic BA400; A- D, x400
magnification; E, x630 magnification.
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Figure 4-2 IL-13 expression at the conjunctiva. Conjunctival biopsies stained for IL-
13 expression as indicated in figure 4-1 were graded based on their staining intensity in
the epithelium (A) and stroma (B). Intensity of IL-13 staining from non-inflamed
controls (n = 3), SAC (n = 3), GPC (n = 3), VKC (n = 6) and AKC (n = 3) were scored
between 0-3 where 0 = no staining, 1 = weak, 2 = moderate, 3 = strong staining. Results
are shown as mean ± SD. * p<0.05
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Figure 4-3 IL-13 mRNA is expressed at the ocular surface and increased in
AKC. Conjunctival swabs taken from normal (n = 16), OCP (n = 35) and AKC (n =
7) subjects were used to isolate RNA. The expression of mRNA for IL-13 was
assessed by real-time RT-PCR. Each symbol represents an individual and lines
indicate the mean expression. * p <0.05; ** p <0.01.
4.2.2 IL-13 expression in conjunctival epithelial cells
So far, we have demonstrated that IL-13 is expressed at the conjunctival surface and
is upregulated in CAED. Part of this expression was attributed to CD3+ T cell
expression of IL-13. In those sections where IL-13 staining alone was detected on the
epithelium, its cellular source was unknown. One hypothesis is that the conjunctival
epithelium secreted IL-13 in response to the cytokines that are associated with
CAED pathogenesis. To investigate whether conjunctival epithelial cells secrete IL-
13, the IOBA and ChWK cell lines were used and cells were stimulated for 24 and
48 hours in the presence of PMA, IFN-γ, IL-4, poly I:C, IL-1β, or TNF-α ± IL-1β.  
There were no detectable levels of IL-13 secreted by either conjunctival epithelial
cell lines, suggesting that the staining observed is of IL-13 binding to the surface of
the epithelium, and not secretion by conjunctival epithelial cells.
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4.2.3 IL-13 mRNA expression in the conjunctiva
Although the conjunctival epithelial cells did not secrete IL-13, we wanted to
confirm this finding by looking at IL-13 mRNA expression in the cell line. In this
experiment only the IOBA cell line was used, the cells were treated with various
stimuli for 1, 4, 6 and 24 hours before harvesting to isolate RNA and quantitate using
real-time RT-PCR.
The expression of IL-13 mRNA could be found in all cells receiving treatment after
4, 6 and 12 hours, but there were no significant differences between the groups (data
not shown). In contrast treatment of the cells for 1 hour with TNF-α, IL-4 or IL-13 
led to significantly increased expression of IL-13 (p<0.05 in all). TNF-α synergised 
with IL-4 and IL-13 to significantly upregulate IL-13 expression (p<0.01; Figure 4-
4A). As well as the pro-inflammatory and Th2 cytokines, all three TLR agonists -
zymosan (p<0.05), poly I:C (p<0.01) and LPS (p<0.05) – induced significant
increases in IL-13 expression. Of these, poly I:C appeared to have a greater effect
above zymosan and LPS but this failed to reach significance (Figure 4-4B).
From this data we can speculate that IL-13 may be involved in CAED and although
conjunctival epithelial cells do not secrete this cytokine, the ability to induce IL-13
mRNA expression in these cells leads us to assume that epithelial cells may be
involved in supporting the IL-13 environment seen in CAED.
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Figure 4-4 IL-13 mRNA expression can be induced in conjunctival epithelial
cells. IOBA cells were either left untreated or treated with pro-inflammatory and
Th2 cytokines (A) and TLR agonists (B) for 1 hour. Cells were harvested and RNA
was isolated before conversion to cDNA by reverse transcription. IL-13 mRNA was
analysed by real-time RT-PCR and the house keeping gene β-actin was run in 
parallel. * p<0.05; ** p< 0.01
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4.3 TSLP is expressed throughout the conjunctiva in CAED
There are many mechanisms that may contribute to the pathogenesis of CAED; one
hypothesis currently being explored involves the epithelial cell derived cytokine
TSLP, which has been reported to be increased in inflamed tissues of the skin and
lungs (Soumelis et al, 2002; Ying et al, 2005). As the epithelium of the conjunctival
surface shares many properties with other mucosal sites, we speculated that like that
of the lungs, the conjunctival tissues of CAED subjects will also show increased
expression of TSLP. It has recently been reported that primary human conjunctival
epithelial cells can be induced to upregulate TSLP transcripts and significantly
increase TSLP protein production by poly I:C stimulation (Ueta et al, 2010).
4.3.1 TSLP expression at the ocular surface
To examine the expression of TSLP, GMA embedded conjunctival biopsy sections
were stained by immunohistochemistry. The sections were also graded using a 4
point scale to demonstrate staining intensity.
Using an AKC section stained with a control antibody as our negative control, we
detected some background staining (Figure 4-5A). The normal controls (Figure 4-
5B) and SAC sections (Figure 4-5C) did not show any detectable TSLP expression.
In comparison in CAED sections a very strong expression of TSLP was observed
(Figure 4-5D and E). Within the AKC and VKC sections TSLP expression appears to
be continuous in the epithelium and stroma in AKC sections (Figure 4-5D), whilst
the staining found in VKC sections is very intense in the epithelium (Figure 4-5E)
compared to AKC.
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The staining results were graded based on TSLP staining intensity. TSLP expression
within the epithelium was significantly increased in VKC than in AKC (p<0.05;
Figure 4-6A). The distribution of TSLP expression in the stroma was less variable
(Figure 4-6B); there were no significant differences between the two different forms
of allergic eye disease. Also, the grading revealed that although epithelial TSLP was
absent in SAC sections, within the stroma there was some expression evident (Figure
4-6B).
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Figure 4-5 TSLP is localised to the conjunctival epithelium of CAED tissues.
Conjunctival biopsies taken from (A) AKC (n = 5; IgG control), (B) non-inflamed
control; n = 3, (C) SAC; n = 3, (D) AKC; n = 5 and (E) VKC; n =5, were evaluated for
TSLP expression by immunohistochemical staining. Arrows pointing to brown staining
indicate TSLP expression. Images were captured with Motic BA400; A and E, x200
magnification; B-D, x400 magnification.
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Figure 4-6 TSLP is upregulated in the conjunctival epithelium in VKC tissues.
Conjunctival biopsies obtained from 18 subjects; non-inflamed controls (n = 3),
SAC (n = 3), GPC (n = 3), VKC (n = 6) and AKC (n = 3), were stained for TSLP
expression as described in figure 4-2. Biopsies from each subject were graded on the
basis of TSLP staining intensity in the epithelium (A) and stroma (B) and scored
between 0-3 where 0 = no staining, 1 = weak, 2 = moderate, 3 = strong staining.
Results are shown as mean ± SD. * p<0.05.
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4.3.2 TSLP protein production
Our findings demonstrated TSLP localisation in the epithelium of CAED tissues, this
led us to examine whether TSLP is also secreted by conjunctival epithelial cells
which has been reported to be expressed by bronchial epithelial cells (Kato et al,
2007). Based on their study, both IOBA and ChWK epithelial cells where treated
with PMA, IFN-γ, IL-4 ± IL-1β, IL-13 ± IL-1β, , IL-1β, TNF-α ± IL-1β or poly I:C 
for 4, 24 and 48 hours. Supernatants were assayed for TSLP secretion by ELISA.
Both conjunctival cells lines had very minimal secretion of TSLP; the minimal
detectable range for the ELISAs was 40pg/ml (Figure 4-7A & B). As Kato et al had
shown TSLP secretion in bronchial epithelial cells, we used a bronchial cell line
(16HBE) in parallel as a positive control. Like the conjunctival cells lines there was
very low secretion of TSLP with the majority of treatments at all time points (data
not shown), but treatment with poly I:C (p<0.01) and PMA (p<0.01) after 24 hours
significantly upregulated TSLP secretion above untreated cells. Poly I:C also had the
greatest effect in inducing TSLP secretion compared to PMA treated (p<0.01)
(Figure 4-7C).
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Figure 4-7 TSLP is secreted by human epithelial cells. Two human conjunctival
epithelial cell lines; IOBA (A) and ChWK (B) and a bronchial epithelial cell line
[16HBE] (C) were treated with various stimuli for 4, 24 and 48 hours. Supernatants
were collected at each time point and assayed for TSLP secretion by ELISA. Results
are taken from five independent experiments and are shown as mean ± SEM of the
stimulations where TSLP was above the minimum detectable range. **p <0.01
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4.3.3 TSLP mRNA is expressed in conjunctival epithelial cells
Unlike our finding and other reports citing TSLP secretion in bronchial epithelial
cells, we were unable to detect secretion of this cytokine by conjunctival epithelial
cells. As with IL-13 we sought to determine whether conjunctival epithelial cells
express TSLP at the mRNA level. Of the different treatments that were used to
address TSLP secretion in this study, we focussed on IL-4, IL-13 and their
combination with TNF-α as well as TLR agonist, especially poly I:C which has been 
demonstrated to significantly upregulate TSLP mRNA (Kato et al, 2007). Cells were
treated for 4 and 6 hours before harvesting and RNA isolation. Quantification was
carried out by real-time RT-PCR.
At the 6 hour time point, both unstimulated and stimulated cells expressed TSLP
mRNA, indicated by their cycle threshold values but there was no difference
observed between the groups (data not shown). Within 4 hours of the cells being
treated TNF-α stimulation significantly upregulated TSLP expression (p<0.01).
Combination of TNF-α with IL-4 or IL-13 did not augment the level of expression. 
On their own, IL-4 and IL-13 also upregulated TSLP mRNA, IL-13 had the greatest
effect increasing expression up to 150 fold (Figure 4-8A). All the TLR agonists
induced significant upregulation of TSLP mRNA (p<0.01 in all), at least almost 200
fold compared with previous stimulations. Of the three TLR agonists, poly I:C
treatment produced the greatest increase though it was not significantly higher
(Figure 4-8B).
Taken together we can say that there is a strong association with TSLP and its role in
CAED, which is especially apparent in VKC. Although the conjunctival epithelial
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cells used did not secrete TSLP, we were able to show that in an inflammatory
environment these cells are capable of inducing TSLP mRNA, which may in time be
secreted in the right conditions.
Figure 4-8 TSLP mRNA is expressed by conjunctival epithelial cells. The
conjunctival epithelial cell line (IOBA) were treated with pro-inflammatory and Th2
cytokines (A) and TLR agonists (B), cells were harvested and RNA isolation was
carried out. RNA was reverse transcribed and assayed for TSLP expression by real-
time RT-PCR. The house keeping gene β-actin was assayed in parallel to account for 
any variations in the amount of cDNA in each sample. Results are shown as relative
fold increase with unstimulated cells given a value of 1. ** p<0.01
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4.4 Discussion
In the different forms of allergic conjunctivitis, the inflammatory environment of the
conjunctiva is clearly influencing the development of the various disorders. As with
current literature, we have been able to identify increased IL-13 expression at the
ocular surface as well as the ability for conjunctival epithelial cells to express IL-13
mRNA when stimulated with inflammatory cytokines and TLR agonists. More
interestingly, the proallergic Th2 cytokine, TSLP, is found to be increased in CAED.
Most studies have shown that TSLP is mainly induced by the TLR3 agonist – poly
I:C, this data also confirms that finding and shows that TSLP mRNA in conjunctival
epithelial cells can be upregulated under Th2 inflammatory conditions as well as
with TLR agonists.
Th2 derived cytokines such as IL-13 are important in the promotion of allergic
inflammation. This cytokine has been found in significantly increased levels in tear
specimens from subjects with SAC, VKC and AKC in comparison to controls
(Leonardi et al, 2006). Our study has also demonstrated the expression of IL-13 in
SAC and CAED conjunctival tissue sections, with CAED tissues showing very
strong IL-13 staining and IL-13 positive goblet cells in SAC tissues. Although there
was very intense staining of this cytokine, it may not represent actual secretion of IL-
13 from epithelial cells but in fact binding of the cytokine to the epithelium. This
idea is supported by the undetectable levels of IL-13 in the culture supernatants. IL-
13 does appear to be expressed by, and not bound to CD3+ T cells since CD3+ T cells
do not have receptors for IL-13. Previous reports support this finding as high levels
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of IL-13 have been shown to be produced by conjunctival T cell lines derived from
AKC and VKC subjects (Calder et al, 1999). The CD3+ T cells in the biopsies may
therefore be secreting IL-13 which is, in turn, binding to the epithelium. This further
adds to the evidence that the chronic allergic inflammatory process is dependent on
the expression of Th2 derived cytokines, perhaps secreted also by mast cells present
at the site of inflammation.
There is no evidence of IL-13 secretion by epithelial cells but IL-13 is also present in
goblet cells in VKC and AKC sections and it has been reported that IL-13 induces
goblet cell hyperplasia of human airway epithelial cells in vitro (Atherton et al,
2003) and mucin production observed in rat models (Shim et al, 2001). This may
prove true in VKC and AKC tissues as the source of IL-13 may be due in part to
CD3+ T cells; however it does not explain the expression of IL-13 seen in goblet
cells of SAC conjunctival tissue, as there were no CD3+ T cells present here. It may
be possible that the increased numbers of goblet cells shown in SAC conjunctival
tissue, compared to the controls, may have been as a result of IL-13 secreted by mast
cells, which are increased in numbers in SAC (Anderson et al, 1997). This in turn
may have led to the increased proliferation of goblet cells leading to mucus
hypersecretion. The mechanism responsible for the presence of IL-13 in the goblet
cells is unknown and further work will have to be carried out to elucidate the origin
of IL-13 in these tissues.
It has already been reported that there is a role for TSLP in the development of
inflammation (Al-Shami et al, 2005). It has also been linked to allergic diseases. This
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theory has been supported by findings that the expression of TSLP is increased from
cells within the bronchial epithelium and submucosa in asthmatics (Ying et al, 2005)
and acute and chronic atopic dermatitis lesions (Soumelis et al, 2002) and TSLP
expression here correlates with disease severity (Ying et al, 2005). These findings
may therefore also be true for those with chronic forms of allergic eye disease (AKC
and VKC), where TSLP was highly expressed in comparison to milder conditions
such as SAC, therefore supporting the idea that TSLP is associated with the severity
of disease, with epithelial cells being central to this pathogenesis.
The difference in TSLP expression demonstrated between VKC and AKC sections
and the low level expression of this cytokine in the epithelium of SAC sections may
be due in part to the functional characteristics of TSLP. Ying et al reported that
TSLP is implicated in asthma pathogenesis, which may be acting through the Th2
cells whose cytokines are responsible for much of the disease pathogenesis (Ying et
al, 2005). In allergic conditions such as that of SAC, Th2 cytokines are predominant
(Fujishima et al, 1997) which is also seen in subjects with VKC (Metz et al, 1997).
The reverse is true for AKC subjects, where there is a more Th1-skewed cytokine
profile (Metz et al, 1997). Although T cells are not found in SAC, the actions of
TSLP may be driving cells capable of secreting Th2 type cytokines, such as
eosinophils or mast cells. These differences in cytokine profiles may account for the
differences in TSLP expression seen between VKC and AKC, where production of
TSLP leads to a more Th2 permissive environment like that seen in VKC.
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It has been postulated that upon stimulation of the epithelium, in this case airway
epithelial cells, these cells can be induced to secrete TSLP. In these studies the
combination of TNF-α and IL-4 or IL-13  proved to be the most effective stimulation 
for the epithelial cells (Kato et al, 2007) as well as airway tissues from patients with
asthma (Huang et al, 1995). TNF-α and IL-1β as well as double stranded RNA such 
as poly I:C (Allakhverdi et al, 2007) were also shown to be effective stimuli. In vivo
we have shown that TSLP is expressed in conjunctival tissues from CAED patients.
It was therefore important to go back and look at in vitro models. Our data was only
able to demonstrate TSLP secretion in the bronchial epithelial cell line (16HBE) and
only following PMA and poly I:C stimulation. While evidence for TSLP mRNA
expression does not prove that it is secreted at the protein level by the cells, it does
give us an indication of how the cytokine milieu may alter the characteristics of
conjunctival epithelial cells. We were able to show that TSLP mRNA expression can
be upregulated in line with recent data that has shown expression of TSLP mRNA in
CAED tissues as well as increased TSLP mRNA in a primary human conjunctival
epithelial cell line stimulated with poly I:C (Matsuda et al, 2010). More interestingly,
one study has defined a role for TSLP and its dependency on IL-13 to induce cell
proliferation and wound closure in asthmatic bronchial epithelial cells (Semlali et al,
2010).
The investigation into IL-13 and TSLP at the ocular surface has allowed us to add to
the growing body of evidence that both cytokines are involved in allergic
conjunctivitis. By showing IL-13 treatment of conjunctival epithelial cells enhances
TSLP mRNA expression we have demonstrated what may be a causal link between
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IL-13 and TSLP expression. At this point it is not enough to say that Th1 and Th2
cells and cytokines only contribute to CAED pathogenesis. Other T helper subtypes
have been implicated and are thought to play a role in chronic disease, which will be
the focus of the next study.
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Th17 cells infiltrate the conjunctiva, epithelial cells of which
respond to IL-17
5.1 Introduction
The pathogenesis of Th17 cells in human inflammatory disorders has been the
subject of much debate. As well as Th1 and Th2 cells, Th17 cells have been found to
be present in inflamed tissues of patients suffering from psoriasis, arthritis, Crohn’s
disease and severe asthma (Pène et al, 2008). It is thought that the IL-17 produced by
these cells may contribute to the pro-inflammatory environment observed in
inflammatory disorders. As well as a pro-inflammatory role, it has been described
that Th17 cells are important in host defence towards bacterial and fungal pathogens.
This protective function has been reported to work through differing actions such as
neutrophil recruitment via IL-8 induction by IL-17, as well as the production of
chemokines thereby permitting the recruitment of protective IFN-γ producing CD4+
T cells (Wu et al, 2007; Khader et al, 2007). It has also been shown that knockout
mice lacking IL-17A and IL-17F have decreased expression of the antimicrobial
peptide important in host defence, β-defensin (Ishigame et al, 2009). Although
known as the signature cytokine for Th17 cells, IL-17A as well as IL-17F can be
produced by a number of other cell types such as γδ T cells, NKT cells, NK cells, 
neutrophils and eosinophils (Korn et al, 2009).
The pathogenesis of CAED has been described as involving CD4+ T lymphocytes,
namely that of mainly Th1 in AKC and Th2 in VKC, as shown by their cytokine
profile during disease (Metz et al, 1997; Calder et al, 1999). Both disorders have
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other cell types present in inflammatory areas of the conjunctival tissues such as mast
cells which have been found in AKC and increased in the conjunctival epithelium of
VKC (Foster et al, 1991; Abu el-Asrar et al, 1989). Mast cells are characterised by
their ability to produce an array of mediators such as histamine and cytokines,
including IL-4, IL-5, IL-8 and IL-13, giving these cells the ability to initiate allergic
inflammation (Church & Levi-Schaffer, 1997; Anderson et al, 2001). More recently
it has been observed that in the synovium of joints affected by RA, the majority of
mast cells found were IL-17A+ and stimulation of mast cells in vitro induced IL-17A
production (Hueber et al, 2011).
With such interplay of cells at the conjunctiva in CAED it is impossible to say which
cells and their cytokines are taking part in the pathogenesis of the disease, especially
with the emergence of Th17 cells. The aim of this chapter is to establish whether
Th17 cells are present in conjunctival tissues and if their levels vary during CAED
and to determine the effects of IL-17 at the conjunctival surface.
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5.2 Th17 cells infiltrate the conjunctival epithelium in CAED
In the past it was widely thought that the pathogenesis of certain diseases was
through the actions of Th1 or Th2, for example RA was described as Th1 mediated.
With the discovery of Th17 cells many studies have been trying to ascertain whether
this disease is Th1 mediated or Th17 mediated (Yamada et al, 2008). As Th17 cells
have been found in various inflamed sites (Pène et al, 2008), we sought to determine
whether these cells are also present in the tissues of CAED, which has been reported
to be either Th1 or Th2 mediated.
5.2.1 Th17 cells are localised to the conjunctiva in CAED
To examine whether there is a correlation between chronic diseases affecting the eye
and Th17 cells, conjunctival biposy sections were stained for co-expression of CD4
T cells and IL-17 in normal controls, SAC, OCP, VKC and AKC. The normal
control sections were negative for both CD4+ T cells and IL-17 (Figure 5-1A); this
was also observed in SAC tissues, which were negative in all sections (Figure 5-1B)
whilst in OCP tissues few CD4+ T cells and IL-17+ cells were present (Figure 5-1C).
In contrast, increased numbers of CD4+ T cells appeared to be infiltrating areas of
VKC tissues (Figure 5-1D) and in the same section, CD4+ IL-17+ T cells were
observed localising to the conjunctival epithelium (Figure 5-1E). Similarly in AKC,
CD4+ IL-17+ T cells were found within areas of the epithelium as well as in the
stroma (Figure 5-1F).
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Figure 5-1 Th17 cells localise to the conjunctival epithelium in CAED tissues.
Conjunctival biopsies were immunohistochemically stained for the expression of Th17
cells, characterised by CD4+ IL-17+ cells. Sections were double stained for CD4 (red)
and IL-17 (brown), combined the cells have a very dark colouration; (A) normal
control; n = 6 [double stain, CD4 and IL-17], (B) SAC; n = 6 [double stain, CD4 and
IL-17], (C) OCP; n = 5 [double stain, CD4 and IL-17], (D) VKC; n = 6 [1L-17] (E)
VKC; n = 6 [double stain, CD4 and IL-17] , (F) AKC; n = 6 [double stain, CD4 and IL-
17]. Arrows indicate positive stained cells. Images were captured using Motic BA400;
A - D, x200 magnification; and E - F, x630 magnification.
A B
C D
E F
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5.2.2 Th17 attracting chemokines are preferentially secreted by
conjunctival epithelial cells
As we have detected an infiltration of Th17 cells in the conjunctival tissues in
CAED, it was important to ascertain whether the conjunctival epithelium can
orchestrate T cell infiltration into the area, especially that of Th17 cells. Certain pro-
inflammatory cytokines that have been observed in the conjunctiva of subjects with
CAED were used to stimulate conjunctival epithelial cells as well as co-culturing
with pre-activated mast cells. Their supernatants were collected and assayed for
secretion of Th1, Th2 and Th17 attracting chemokines by ELISA.
After 24 hours there was minimal secretion of the Th1 attracting chemokine
CXCL10 in poly I:C – and TNF-α + IL-1β – treated epithelial cells whilst the 
combination of these treatments significantly augmented the production of this
chemokine (Figure 5-2). In contrast, after 48 hours treatment CXCL10 secretion was
detected in unstimulated cells and significantly upregulated with all treatments.
There did not appear to be any difference between epithelial cells treated with TNF-α 
+ IL-1β alone or in combination with poly I:C, except in epithelial cells cultured with 
non-activated CBMCs (Figure 5-2A) or in poly I:C treated CBMCs (Figure 5-2F).
However, the addition of CBMCs to epithelial cells did not augment this response as
the levels of CXCL10 were similar between the different epithelial treatments that
had been cultured with untreated or treated CBMCs.
In the same way we also wanted to determine whether the epithelial cells secreted the
Th2 attracting chemokine – CCL17, but unlike CXCL10 the level of CCL17 was
undetectable.
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Another chemokine studied was CCL20, the Th17 attracting chemokine. Secretion of
this chemokine was observed after 24 hours even with unstimulated epithelial cells
and it was significantly upregulated after IL-17 and poly I:C treatment (p<0.01).
Upon treatment with TNF-α + IL-1β and its combination with poly I:C, the response 
was more pronounced, combination of these treatments failed to have a synergistic
effect (Figure 5-3). After 48 hours there was only a slight diminution of CCL20
secretion in the majority of cells. There also appeared to be a synergistic effect
between poly I:C + TNF-α + IL-1β treated cells cultured with poly I:C treated 
CBMCs (p<0.05; Figure 5-3F).
The localisation of Th17 cells in the conjunctiva of CAED tissues has led us to the
idea that this cell type may play a role in disease. Although the conjunctival
epithelium secretes Th1 attracting chemokines, we have shown that CCL20 is
produced within the first 24 hours and is sustained over 48 hours. This could indicate
that Th17 cells may be the first T cell subset to infiltrate diseased areas, followed by
Th1 then Th2 cells, depending on the inflammatory environment of the particular
disease. This data, although being insightful, is unable to establish whether Th17
cells are pathogenic in CAED.
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Figure 5-2 The Th1 attracting chemokine – CXCL10 is secreted greatly in the
later stages of stimulation. IOBA cells were either left untreated or stimulated with IL-
17, poly I:C, TNF-α + IL-1β for 24 hours before being cultured with CBMCs that had 
been unstimulated (A) or treated with (B) IgE, (C) IL-17, (D) TNF-α+IL-1β, (E) PMA
and (F) poly I:C. Supernatants were collected after 24 (open bars) and 48 hours (black
bars) and assayed for CXCL10 by ELISA. Results are shown as mean ± SD of three
separate experiments; * p <0.05, ** p <0.01.
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Figure 5-3 The Th17 attracting chemokine – CCL20 is preferentially secreted in
the early phase of stimulation and is sustained over 48 hours. IOBA cells were either
left untreated or stimulated with IL-17, poly I:C, TNF-α + IL-1β for 24 hours before 
being cultured with CBMCs that had been (A) unstimulated or treated with (B) IgE, (C)
IL-17, (D) TNF-α+IL-1β, (E) PMA and (F) poly I:C. Supernatants were collected after 24
(open bars) and 48 hours (black bars) and assayed for CCL20 by ELISA. Results are
shown as mean ± SD of three separate experiments; * p <0.05, ** p <0.01.
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5.3 IL-17 can be found at sites of conjunctival tissues
The actions of IL-17 have been given two differing roles, one of mediating
pathogenesis the other of protecting the host from infection. As Th17 cells have been
found to be localised in CAED tissues, it is important to determine whether the
ocular surface has the ability to produce IL-17 and other Th17 related cytokines,
therefore shedding a light on any further cytokines that may be participating in the
inflammatory environment seen in disease.
5.3.1 IL-17 is expressed in the conjunctiva and increased in CAED
In addition to its co-localisation to CD4+ T cells we also examined IL-17 expression
on non-T cells in CAED tissues. Compared to OCP tissues (Figure 5-4A) we found
increased intensity of IL-17 staining on the epithelium and stroma in CAED (Figure
5-4 B), the level of which was not found to be restricted to any particular area but
widespread throughout the tissue. In conjunction we quantified the level of IL-17
staining intensity in all the tissues. Within the epithelium we could not identify any
IL-17 expression in the normal controls and only minimal expression in SAC and
OCP tissues, which was significantly upregulated in CAED tissues (p<0.05). In the
stroma we detected expression of IL-17 in OCP which was increased significantly in
CAED tissues (p<0.05), this expression did not differ between the epithelium and
stroma (Figure 5-4C).
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Figure 5-4 IL-17 is found at the conjunctival epithelium of CAED tissues.
Conjunctival biopsy sections stained as in figure 5-1 were also evaluated for their
expression of IL-17. Positive IL-17 staining is depicted by brown staining; (A) OCP,
(B) AKC. Intensity of IL-17 staining (C) was quantified by grading sections from
normal controls (n = 6), SAC (n = 6), OCP (n = 10), CAED (VKC – n = 4; AKC – n =
5). Sections were scored between 0-3 where 0 = no staining, 1 = weak, 2 = moderate, 3
= strong staining. Results are shown as mean ± SEM. * p <0.05
5.3.2 IL-17 mRNA is expressed at the conjunctival surface
To further investigate the expression of IL-17 at the conjunctiva, mRNA from
conjunctival swabs was isolated and assayed to quantify their expression of IL-17
mRNA. The results indicate the expression of IL-17 in controls as well as in OCP
and AKC specimens. Although not significant, there was increased expression of IL-
17 in AKC above that of normal controls and OCP specimens. In using this method
we are unable to establish which cell type is responsible for the IL-17 expressed here,
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in such a case it would be interesting to determine whether conjunctival epithelial
cells are capable of producing this cytokine.
Figure 5-5 IL-17 mRNA is expressed at the conjunctival surface. RNA was
isolated from conjunctival swabs taken from normal (n = 16), OCP (n = 35) and
AKC (n = 7) subjects. The expression of IL-17 mRNA was evaluated by real-time
RT-PCR. Each symbol represents an individual and lines indicate the mean
expression.
5.4 Conjunctival epithelial cells produce IL-17 related cytokines
So far this study has shown that the chemokine involved in Th17 infiltration is
produced in high levels by conjunctival epithelial exposed to pro-inflammatory
cytokines and a TLR agonist, which may explain the Th17 cells observed at
conjunctival sites. Just as the conjunctiva in CAED has demonstrated high IL-17
staining intensity in both the stroma and epithelium, we wanted to confirm whether
the IL-17 seen in the tissues was produced from epithelial cells. To examine this we
stimulated IOBA cells and assayed their supernatants for the presence of cytokines
from the IL-17 family.
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Contrary to the IL-17 staining observed in the tissue sections (Figure 5-5B);
conjunctival epithelial cells were unable to produce the major Th17 cell cytokines
IL-17A and IL-17F, nor did they produce IL-22 or IL-23. Nevertheless, in the
presence of poly I:C, the cells were induced to secrete significantly higher levels of
IL-25 (IL-17E; p<0.01) compared to the relatively lower levels observed in
unstimulated cells and cells cultured with other treatments (Figure 5-6).
Figure 5-6 IL-25 (IL-17E) is secreted by conjunctival epithelial cells
stimulated by a TLR3 ligand. IOBA cells were stimulated with a panel of
treatments for 24 hours after which supernantants were collected and used to assay
IL-25 production by ELISA. Experiments were repeated four times and results are
shown as mean ± SEM of the four experiments; ** p <0.01.
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5.5 IL-17 stimulates conjunctival epithelial cells to produce
pro-inflammatory cytokines.
It is thought that IL-17 mediates its pathogenic activity via its ability to induce
proinflammatory cytokines as well as chemokines such as TNF-α, IL-1β, IL-6 and 
IL-8 (Onishi & Gaffen, 2010). These cytokines can then work by exacerbating any
ongoing inflammation whilst chemokines aid in the recruitment of other cells,
thereby increasing further sources of cytokines. To understand whether IL-17
contributes to the pathogenesis of ocular disease, it is necessary to establish if this
cytokine has any effect on conjunctival epithelial cells.
5.5.1 IL-17 induces the secretion of pro-inflammatory mediators
To confirm whether conjunctival epithelial cells can be activated by IL-17, the cells
were treated with IL-17 for 24 hours after which supernatants were assayed for
secretion of IL-8 and sCD44, and CD54 expression in detached cells. In parallel,
stimulated cells were detached in order to isolate RNA and look for mRNA
expression of IL-8, IL-13 and TSLP. In contrast to untreated cells, IL-17 stimulation
caused a significant upregulation of both IL-8 and sCD44 (Figure 5-7A; p<0.01).
This was further confirmed at the mRNA level with significant expression of IL-8
(Figure 5-7B). IL-13 mRNA expression in the cells failed to be altered by IL-17
treatment but the level of TSLP was markedly increased (Figure 5-7B; p<0.01). In
contrast to their ability to upregulate IL-8 and TSLP, IL-17 stimulation did not result
in augmentation of CD54 (data not shown).
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Figure 5-7 IL-17 stimulation induces the production and mRNA expression of
inflammatory markers. IOBA-NHC cells were stimulated for 24 hours with IL-
17A after which supernatants were collected and assayed for IL-8 and sCD44
production (A). Results are shown relative to unstimulated cells. Cells were also
stimulated with IL-17A for 4, 6 or 24 hours upon which cells were detached and
RNA isolated. Using RT-PCR, the level of mRNA for IL-8, IL-13 and TSLP were
analysed (B). Results are shown as mean ± SEM of four experiments for the
production of cytokines and three experiments for mRNA expression; ** p <0.01.
5.5.2 IL-17 promotes the upregulation of MMPs in the epithelium
MMPs have been associated with different disorders and it is thought that they
contribute to inflammation and tissue remodelling. In mice, desiccating stress has
been reported to increase MMP9 as well as Th17 associated genes (De Paiva et al,
2009). To investigate whether pro-inflammatory stimuli, especially IL-17 and TLR
ligands, can induce conjunctival epithelial cells to produce MMPs, cell-free
supernatants from treated cells were assayed for MMP9 production with the use of a
multicytokine bead array. This method was unable to detect MMP9; therefore the use
of a MMP antibody array which is more sensitive in detecting MMP expression was
adopted. In this instance we detected significant changes in MMP2 and MMP9
expression. The intensity of MMP2 (Figure 5-8A) as well as MMP9 expression
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(Figure 5-8B) in IL-17 stimulated cells was found to be significantly increased
compared to unstimulated cells and cells treated with the remaining stimuli (p<0.05).
The intensity of MMP9 expression was also increased in TNF-α + IL-1β treated cells 
but this failed to reach significance. We also detected the expression of MMP1 and
MMP3 which was not altered upon stimulation (data not shown).
Figure 5-8 IL-17 upregulates the expression MMPs. IOBA cells were stimulated with
various treatments, after 24 hours supernatants were collected for use in an antibody protein
array to determine MMP2 (A) and MMP9 (B) expression. Graph represents results from
mean ± SD of three separate experiments; * p <0.05.
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5.6 Discussion
Th17 cells have been implicated in various chronic inflammatory conditions in
addition to playing a part in host defence. In this present chapter we investigated the
expression of a T helper cell subset in tissues of chronically inflamed conjunctiva
and the effect of its primary cytokine – IL-17 on epithelial cell responses. So far we
have found evidence of Th17 cells localising to the conjunctiva of chronically
inflamed tissues and indications that Th17 cells may be the first T cell subset to
arrive at inflamed sites, based on the secretion of CCL20 by conjunctival epithelial
cells as early as 24 hours post treatment. As well as IL-17 mRNA expression found
in conjunctival swabs, inflamed tissues, in particular in CAED, exhibited increased
levels of IL-17 staining. Upon further investigation, IL-17 was capable of stimulating
conjunctival epithelial cells to induce increased pro-inflammatory markers in
addition to upregulating MMPs.
Much like this study only one group have reported the presence of Th17 cells in the
conjunctiva of OCP patients, where OCP specimens were found to have increased
staining of Th17 cells above that of healthy subjects (Lambiase et al, 2009).
Although Th17 cells were present in our biopsy specimens, it is not clear whether
these cells have been recruited and mediate inflammation as part of the disease
pathogenesis or if these cells are responding as part of the defence mechanism
against microbial infection. As just described, in order for CD4+ T cells to take part
in the immune response, they must first be recruited to the specific site, normally
initiated by chemoattractants secreted by other cells in that area, for Th17 cells the
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chemoattractant of interest is CCL20. While there has not been much attention
focusing on secretion of specific chemoattractants by ocular epithelial cells, one
study has described the expression of CCL20 mRNA in primary human conjunctival
epithelial cells, which can be significantly upregulated more than 10-fold after poly
I:C stimulation (Ueta et al, 2010). Furthermore, the authors also noted a significant
increase in CCL20 protein secretion (Ueta et al, 2010). The authors also reported the
same findings with CXCL10, which adds to our data showing both chemokines are
secreted by conjunctival epithelial cells. When we the address the expression of
CCL20 in context with disease it has been shown that 24 hours after the addition of
allergen there is an increase in epidermal CCL20 mRNA in atopic dermatitis patients
(Gros et al, 2009). In contrast, the same study showed that CCL17 – a Th2
chemokine is found to be increased at a later time point – after 72 hours allergen
exposure (Gros et al, 2009). Another role for CCL20 has also been proposed, as an
antimicrobial peptide. Reports have shown that CCL20 peptide is effective in killing
Pseudomonas aeruginosa (Huang et al, 2007), therefore pointing towards a model of
host defence by this conjunctival epithelial cell line.
It is interesting that we were unable to detect CCL17 in our cultures during this
study; some evidence has suggested that this chemokine can be induced in bronchial
epithelial cells. The authors here found that stimulation with TNF-α + IL-4 induced 
CCL17 secretion up to 72 hours in one of their cell lines (Sekiya et al, 2000).
Stimulation of a different bronchial epithelial cell line with the allergen Der P
combined with IL-4 and TGF-β, also significantly increased CCL17 production 
(Heijink et al, 2006). Contrary to this another study demonstrated that CCL17
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protein is not detected in primary human keratinocytes upon stimulation with various
cytokines, whereas a keratinocyte cell line they used in parallel produced this
chemokine without stimulation (Tsuda et al, 2002). Since mast cells are important in
allergic inflammation and they are capable of producing various cytokines such as
TNF-α and IL-4, we began to consider what role, if any, mast cells may play whilst 
in contact with the conjunctival epithelium. Although culturing mast cells with
conjunctival epithelial cells appeared not to have an effect on the secretion of the
various chemokines, one study has examined the effect of histamine on Th1 and Th2
chemokines by keratinocytes. The investigators reported that TNF-α + IFN-γ induce 
both CXCL10 and CCL17 and that through the actions of one of the histamine
receptors (HR1) found on keratinocytes, histamine suppressed CCL17 and enhanced
CXCL10 production (Fujimoto et al, 2011). This may not fully explain why we did
not detect CCL17 in our cultures but as the conjuctiva is known to express histamine
receptors (Bielory & Ghafoor, 2005); it may be an important factor in any future
studies.
Further to the presence of Th17 cells in the biopsies, we also found whole areas of
conjunctival tissue from CAED tissue, exhibiting very strong staining of IL-17 in
comparison to healthy controls. In a study investigating IL-17 in dry eye disease of
mice, CD4+ IL-17+ cells and IL-17 mRNA levels were also found at increased levels
to control (Fukushima et al, 2008; Chauhan et al, 2009). We therefore looked for the
production of Th17 associated cytokines in an attempt to ascertain whether the
conjunctival epithelium secretes IL-17 observed in these sections. Although there
was very intense staining of this cytokine, conjunctival epithelial cells failed to
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produce any IL-17A, IL-17F, IL-22 or IL-23. However, they were able to produce
IL-25 which, in mice is thought to provide a regulatory role to Th17 by inhibiting
Th17 responses and inducing Th2 responses (Kleinschek et al, 2007). As we only
stained for T cell markers, it is impossible to ascertain what other cell type may have
expressed the IL-17. There are a number of candidates that may be responsible
namely gamma delta (γδ) T cells. To date there are no studies focussing on γδ T cells 
in the conjunctiva but recent literature has implicated these cells as being critical in
allergic conjunctivitis. By using a model of allergic conjunctivitis using γδ T cell 
deficient mice, the authors observed a decrease in the clinical signs of allergic
conjunctivitis as well as reduced eosinophil infiltration; this was also associated with
decreased production of Th2 associated cytokines (Reyes et al, 2011). If γδ T cells 
are required for greater expression of allergic conjunctivitis, it would be interesting
to know whether there would be an increase in IL-17 production by these cells,
which may explain the level of IL-17 staining in CAED sections.
Several reports have demonstrated the stimulatory ability of IL-17 on different cell
types. Although this cytokine can upregulate the IL-8 responses by cells, alone it is
not capable of augmenting CD54 expression in human keratinocytes and bronchial
epithelial cells (Albanesi et al, 1999; Kawaguchi et al, 2001), which we too have
now found in conjunctival epithelial cells. This however does not detract from the
growing evidence of a supposed central role for IL-17 in certain pathologies. In
disorders such as rheumatoid arthritis (RA), IL-17 is thought to be involved in matrix
and cartilage degradation. Studies investigating this have revealed the presence of
elevated IL-17 in the serum of RA patients compared to healthy controls, as well as
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the observation that IL-17 was able to upregulate various MMPs (Moran et al, 2009).
At the ocular surface, it is thought that IL-17 has the same effect; in an experimental
model of dry eye, neutralisation of IL-17 resulted in decreased expression of MMP3
and MMP9, possibly leading to dysfunction of the corneal epithelial barrier (De
Paiva et al, 2009). Although we also found increased MMP expression in IL-17
stimulated conjunctival epithelial cells, we can only speculate as to the effect this
may have in CAED pathology.
As a whole, the data from this study suggests that Th17 cells and its cytokine – IL-17
may play a part in CAED, whether this is a supportive or a pathogenic role remains
unclear. Our results have shown IL-17 expression in CAED and we now know that it
has the ability to stimulate conjunctival epithelial cells – but to what end? To answer
these questions the next chapter will aim to uncover the function of IL-17 on
conjunctival epithelial cells by looking at its family of receptors and how this may
have an impact on chronic inflammation.
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IL-17 receptor subsets in tissues and cells
6.1 Introduction
As the previous chapter has discussed, IL-17 is able to drive inflammatory responses
at the mucosal surface; conversely, this cytokine also plays a major role in host
protection. The main Th17 cytokines, IL-17A and IL-17F, both require IL-17RA and
IL-17RC for signalling, which have been found to be coexpressed by fibroblasts,
epithelial and endothelial cells (Toy et al, 2006; Ishigame et al, 2009). Studies have
shown that IL-17 receptor signalling is essential when addressing the protective
response of IL-17. Freitas et al noted that mice deficient in IL-17RA that had been
subjected to polymicrobial sepsis had a significantly reduced survival rate compared
to wild type mice, the authors also observed a significant decrease in neutrophil
migration in the IL-17RA deficient mice (Freitas et al, 2009). Whilst IL-17 receptor
signalling can be beneficial to the host, its actions have been proposed as a major
contributor to the pathogenesis of certain diseases. In a mouse model of arthritis,
blockade or neutralisation of IL-17 resulted in suppression of joint swelling and
inflammation as well as prevention of bone erosion which occurs as a result of joint
inflammation (Koenders et al, 2005)
If we follow this line of reasoning it is possible that if IL-17 receptor signalling - and
therefore IL-17 - has such an influential role in disease pathogenesis, the affected
tissues may also have increased IL-17 receptor expression leading to a greater
inflammatory response. We therefore hypothesised that these receptors may be
upregulated in CAED, which would support our observations that there is a
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significant level of IL-17 staining increased in these inflamed conjunctival tissues.
This chapter will explore this theory in more detail as well as what effects blocking
this receptor might have.
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6.2 IL-17 receptor expression is regulated by pro-inflammatory
cytokines and TLR ligands
The cytokine milieu often found in inflammatory disease can have devastating
effects to the local tissues especially if left unchecked, where it could exacerbate
disease. Studies have shown that under the influence of pro-inflammatory cytokines,
conjunctival epthielial cells can be induced to upregulate HLA-DR, ICAM-1 and two
neuroreceptors (Calonge et al, 2005). As with these receptors, the inflammatory
environment characterised by CAED may also drive IL-17 receptor upregulation.
The following studies will focus on certain molecules that could possibly provoke
such actions.
6.2.1 IL-17 receptor expression is upregulated in CAED
We have already observed the intensity of IL-17 staining to be increased in CAED
tissues (Chapter 5). To determine whether this correlates with a concomitant
expression of receptors for IL-17 on conjunctival tissues, sections were stained for
IL-17RA and IL-17RC. Whilst there is very low expression of IL-17RA at the
epithelial layer in controls (Figure 6-1A), in AKC, IL-17RA expression was detected
along the surface of a section of the subepithelium (Figure 6-1B). In contrast, the
epithelial surface of normal controls had greater expression of IL-17RC than IL-
17RA (Figure 6-1C); this expression was further enhanced in AKC – affected tissues
(Figure 6-1D).
When we graded the intensity of IL-17 receptor expression, we discovered that
whilst both receptors were shown to be expressed at some degree in normal controls,
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SAC and CAED sections, the level of IL-17RC staining was more than that of IL-
17RA when comparing SAC with CAED (Figure 6-1E). Although IL-17RA was
found to be increased in CAED tissues over SAC, it failed to reach significance. The
staining intensity of IL-17RC, on the other hand, was moderate within normal
controls and SAC, whereas in CAED, this expression intensity was significantly
increased in comparison to the two other groups (Figure 6-1E; p<0.05 for both).
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Figure 6-1 IL-17 receptor expression at the conjunctiva. Conjunctival biopsies
were stained for the expression of IL-17RA and IL-17RC by immunohistochemistry;
(A) non-inflamed control [IL-17RA], (B) AKC [IL-17RC], (C) non-inflamed control
[IL-17RC], (D) AKC [IL-17RC]. Images were captured using Motic BA400; A - C,
x400 magnification; D, x200 magnification. Biopsy staining was also graded to quantify
the level of intensity of both receptors (E) from non-inflamed controls (n = 3), SAC (n =
5) and CAED (VKC, n = 5; AKC, n = 4). Staining was also scored between 0-3 where 0
= no staining, 1 = weak, 2 = moderate, 3 = strong staining. Results are shown as mean ±
SD; * p<0.05.
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6.2.2 IL-17RA is upregulated in conjunctival epithelial cells
In earlier chapters we described the response of conjunctival epithelial cells to
certain stimuli, which allowed us to examine whether, under the same stimulation
conditions, these cells can be induced to regulate the expression of IL-17RA.
Unstimulated cells already had a high level of receptor expression, at around 50%,
when we treated the cells with the three separate allergens they failed to augment IL-
17RA expression. Alone, TNF-α + IL-1β significantly upregulated receptor 
expression (p<0.01), and when combined with the different allergens there was
increased expression of IL-17RA but it did not reach significance in any of the
combinations (Figure 6-2A). Upon challenge with IL-17A, there was decreased
expression of IL-17RA, owing to receptor internalisation (p<0.05; Figure 6-2B). This
expression was significantly increased when epithelial cells were exposed to PMA
and poly I:C (p<0.01 and p<0.05 respectively; Figure 6-2B). Although treatment
with zymosan and LPS had no initial affect on IL-17RA expression, when combined
with  TNF-α + IL-1β, there was a significant additive effect when compared to TNF-
α + IL-1β alone (p<0.05 and p<0.01 respectively). Treatment with poly I:C and TNF-
α + IL-1β also resulted in a synergistic effect above that of TNF-α + IL-1β alone 
(p<0.01; Figure 6-2B).
We also investigated the expression of IL-17RC and the relatively unknown IL-
17RD. Both of these receptors were abundantly expressed by conjunctival epithelial
cells, but unlike IL-17RA where treatment with TNF-α + IL-1β upregulated IL-
17RA (Figure 6-2B &C), stimulation of the cells did not result in augmentation in the
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levels of IL-17RC and IL-17RD expression, as illustrated in Figure 6-2D & E. The
histograms show that whilst there is a shift in IL-17RA expression, the same
treatment had no effect above untreated cells (Figure 6-2D & E). As with the
biopsies, the intensity of expression of both IL-17RC and IL-17RD at the
conjunctival epithelium was greater than that of IL-17RA (Figure 6-2D & E). We
can therefore suggest that the conjunctival epithelium expresses at least three of the
IL-17 receptor subtypes, but only speculate as to their relative expression levels in
disease. Of these three receptors, IL-17RA appeared to be the most susceptible to
modulation, possibly due to their low baseline expression. Further examination into
their role in epithelial cell immune responses will be investigated.
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Figure 6-2 Expression of IL-17 receptor subtypes by the conjunctival epithelium. Conjunctival
epithelial cells were treated with various allergens, cytokines or TLR ligands either alone or in
combination with TNF-α+IL-1β. Cells were detached and stained for IL-17RA, expression was 
quantitiated by flow cytometry (A - C). Epithelial cells were also stained for (D) IL-17RC and (E) IL-
17RD. The intensity of receptor expression was compared between histograms C – D, where: - - -
represents IgG control, — represents unstimulated cells and — represents TNF-α+IL-1β treated cells. 
Results are shown as mean ± SEM of four independent experiments; * p<0.05, ** p<0.01.
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6.3 IL-17 receptors mediate conjunctival epithelial cell responses
So far, many reports have discussed a role for IL-17 and IL-17 receptor signalling in
disease pathogenesis. A few groups have found that certain growth factors and
cytokines such as growth regulated oncogene-alpha (GRO-α), IL-1β and TNF-α, 
induced by IL-17, are significantly decreased after receptor blockade (McAllister et
al, 2005; Koenders et al, 2005). As some of these cytokines are pro-inflammatory,
we investigated whether the presence of these cytokines, such as that seen at
inflamed sites may also upregulate IL-17 receptor expression.
6.3.1 IL-17 downregulates conjunctival epithelial cell responses
So far we have reported on the effect of IL-17 on the conjunctival epithelium. To
investigate the contribution of IL-17 receptor expression in epithelial cell responses
to IL-17 and whether the expression of certain surface molecules and chemokines
can be altered, epithelial cells were firstly treated with a panel of stimuli to
upregulate IL-17RA, receptors were then blocked using an anti-IL-17RA antibody or
treated with an isotype-matched control antibody and then cells were re-stimulated
with IL-17A. To determine the concentration of anti-IL-17RA needed to saturate IL-
17RA receptors, the antibody was titrated. As we have observed previously,
unstimulated cells expressed 25-30% IL-17RA and incubation with three different
concentrations of a control antibody resulted in a similar level of expression (Figure
6-3A). However, after incubation with 0.1µg/ml anti-IL-17RA, IL-17RA expression
was diminished by about 40% (p<0.05) and by about 70% with 0.5-1µg/ml of anti-
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IL-17RA (p<0.01 for both; Figure 6-3A). For the remaining experiments 0.5µg/ml of
anti-IL-17RA was used.
In comparison between control antibody treated and anti-IL-17RA antibody treated
cells, there was a significant increase in the level of CD54 expression in those cells
pre-treated with PMA and TNF-α + IL-1β (which have already been shown to 
significantly upregulate CD54) prior to incubation with the control antibody and
further stimulation with IL-17A (p<0.05 for both; Figure 6-3B). Interestingly, pre-
treatment with poly I:C and subsequent stimulation with IL-17A significantly
reduced CD54 expression (p<0.05; Figure 6-3B). Furthermore, with respect to IL-
17RA expression, IL-17A ligation after treatment with the control antibody resulted
in a significant decrease in IL-17RA expression as before, whilst pre-treatment with
TNF-α + IL-1β and poly I:C resulted in significantly increased receptor expression 
when compared to unstimulated cells (p<0.01 for all; Figure 6-3C). When the cells
were treated with anti-IL-17RA, prior stimulation with PMA, TNF-α + IL-1β and 
poly I:C significantly increased IL-17RA expression (p<0.05; p<0.01; p<0.01
respectively; Figure 6-3C) in comparison to unstimulated cells. In this instance, pre-
treatment with IL-17A did not augment receptor expression. When comparing the
two separate treatments, blockade of IL-17RA significantly decreased receptor
expression following poly I:C pre-treatment in comparison to control antibody
treated cells (p<0.01; Figure 6-3C).
To address whether the blockade of IL-17RA affects other epithelial cell responses,
IL-8 levels were also measured. Pre-treatment of the cells before receptor blocking
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demonstrated a similar epithelial cell response as that reported in chapter 3, with
PMA, TNF-α + IL-1β and poly I:C being the main stimulants responsible for 
increased production of IL-8 (data not shown). When the cells were treated with
control antibody, the levels of IL-8 were significantly increased in PMA, and poly
I:C pre-treated cells only (p<0.05; Figure 6-3D). The remaining stimulations failed
to augment IL-8 production above unstimulated cells (Figure 6-3D). These results
indicate our baseline data. A significantly increased production of IL-8 was the result
of cells being pre-activated with IL-17, PMA and poly I:C in the presence of anti-IL-
17RA antibody compared to control antibody (p<0.01, 0.05 respectively; Figure 6-
3D). This suggests that IL-17RA ligation mediates a down-regulation of IL-8.
IL-8 plays a vital role in the immune response namely because it has the ability to
recruit neutrophils to sites of infection, overproduction of which may exacerbate
inflammation. Our findings that IL-17 may in fact decrease the production of IL-8
led us to examine whether levels of another immunoregulatory cytokine TGF-β may 
also be modulated. Pre-treatment with the various stimuli, before the addition of anti-
IL-17RA antibody, appeared to decrease the production of TGF-β1 compared to 
control antibody under the same conditions, although this failed to reach significance
(Figure 6-3E). Surprisingly, unstimulated cells treated with anti-IL-17RA antibody,
significantly down-regulated TGF-β1 secretion in comparison to unstimulated cells 
exposed to control antibody (Figure 6-3E). From this data, epithelial cell responses
appear to deviate from their expected response following IL-17A ligation, this
divergence may provide IL-17A with the capacity to carry out a regulatory role.
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Figure 6-3 The conjunctival epithelial cell response to IL-17 receptor ligation and blockade.
The anti-IL-17RA mAb used for these experiments were titrated using three different concentrations
(0.1 – 1.0μg/ml) along with and IgG control. Conjunctival epithelial cells were left untreated or 
treated separately with the control antibody of anti-IL-17RA mAb for 2 hours. Detached cells were
stained for IL-17RA expression and analysed by flow cytometry (A). For the remaining experiments,
0.5μg/ml of both control antibody and anti-IL-17RA mAb were used. Epithelial cells were pre-treated 
for 24 hours with the panel of stimuli then incubated for 2 hours with control antibody or anti-IL-
17RA mAb, after which all cells were stimulated with IL-17A for 24 hours. Detached cells were
stained for CD54 (B) and IL-17RA (C), whilst cell-free supernatants were assayed for IL-8 (D) and
TGF-β1 (E; medium alone contained 1656.72pg/ml ± 11.22 which was subtracted from TGF-β cell 
production). Results are shown as mean ± SEM from three independent experiments; open bars
represent control treated cells and solid bars represent anti-IL-17RA treated cells * denotes
comparison between unstimulated and stimulated cells under the same conditions, ‡ denotes
comparison between opposing conditions; */‡ p<0.05; **/‡‡ p<0.01.
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6.3.2 A role for IL-17 in lymphocyte proliferation
At this stage, two lines of evidence had been investigated that pointed towards a
possible regulatory role for IL-17, which included the question as to the differential
levels of TGF-β1 between unstimulated cells and cells that received stimulation prior 
to anti-IL-17RA treatment. To address whether conjunctival epithelial cells, after IL-
17A ligation (control antibody treated cells) are proficient in inhibiting lymphocyte
proliferation, through the actions of TGF-β1, we titrated a range of concentrations of 
supernatants from the treatments that reflected strong epithelial cell responses and
cultured them with anti-CD3/28 stimulated CFSE-labelled PBMCs. In parallel,
unstimulated and anti-CD3/28 stimulated CFSE-labelled PBMCs were cultured alone
as controls and proliferation measured by flow cytometry.
To measure the percentage of proliferation, a gate was drawn around the area where
proliferating lymphocytes, based on cell size and granularity were found. A marker
was drawn to indicate undivided cells from unstimulated cultures, shown by the lack
of CFSE dilution (Figure 6-4A); percentage division of stimulated cells was shown
by an increase in CFSE dilution (Figure 6-4B).
As expected there was minimal lymphocyte proliferation in the unstimulated
lymphocyte population in contrast to stimulated cells where there was up to 50%
proliferation. The addition of 5% culture supernatant from all cell treatments, did
appear to inhibit lymphocyte proliferation, although there was only a significant
decrease with supernatants from unstimulated cells treated with control antibody and
PMA – anti-IL-17RA treated cells (p<0.05; Figure 6-5A). In the presence of
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unstimulated – anti-IL-17RA supernatants, the level of proliferation was significantly
reduced compared to control antibody (p<0.05; Figure 6-5A). Lymphocytes cultured
with 10% culture supernatants from unstimulated and PMA pre-treated cells, prior to
the addition of control antibody or anti-IL-17RA resulted in reduced lymphocyte
proliferation (p<0.05; Figure 6-5B). Between the two antibody treatments,
lymphocyte proliferation was significantly inhibited when cultured with supernatants
from unstimulated cells that had received anti-IL-17RA, compared to control
antibody (p<0.01; Figure 6-5B). Supernatants from TNF-α + IL-1β treated cells 
appeared to decrease proliferation, but this did not reach significance. Interestingly,
lymphocytes in the presence of supernatants from poly I:C – control antibody treated
cells were observed to have reduced levels of proliferation (p<0.05), more so than
anti-IL-17RA when comparing between the two (p<0.05; Figure 6-5B). Although
there was a significant decrease, in some instances, in the proliferation of
lymphocytes cultured with 5 and 10% culture supernatant, it remained that with all
the treatments the 20% concentration had the strongest effect, inhibiting lymphocyte
proliferation by about 50% (Figure 6-5C).
This data could not confirm whether IL-17 plays a regulatory role, possibly due to
the experimental design. However, the conjunctival epithelium has been reported to
express TGF-β mRNA (De Paiva et al, 2009) and therefore may still be able to
dampen lymphocyte actions through constitutive production of TGF-β.     
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Figure 6-4 CFSE dilution profile. Unstimulated and stimulated PBMCs labelled
with CFSE were cultured alone or in the presence of epithelial cell supernatants for
5 days. After this time cells were harvested and analysed by flow cytometry. A
marker was positioned to set the area of cell proliferation as shown by unstimulated
PBMCs (A) indicating the baseline levels of undivided cells. As dividing cells lose
their intensity of CFSE after each division, indicated by arrows (CD3/28 stimulated
PBMCs; B), the marker was used to record CFSE dilution and hence the percentage
of proliferation. Proliferation experiments were repeated three times and the means
taken for each condition.
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Figure 6-5 Inhibition of human lymphocytes by conjunctival epithelial cell products. The effect
of the epithelial cell response on human lymphocyte proliferation was measured by culturing
lymphocytes stained with CFSE for 5 days with supernantants collected from the IL-17RA blockade
experiments. Lymphocytes were also stimulated with CD3/28 as well as an unstimualted control and
analysed by flow cytometry. Analysis was conducted by gating on the lymphoblast region and looking
at CFSE dilution in that population – indicating proliferating cells. Percent proliferation in comparison
with CD3/28 stimulated lymphocytes was taken for lymphocytes cultured with 5% (A), 10% (B) and
20% (C) epithelial cell supernatants. Results are shown as mean ± SEM; * denotes comparison to
CD3/28 stimulated cells, ‡ denotes comparison between opposing conditions; */‡ p<0.05; ‡‡ p<0.01.
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6.4 Discussion
It has already been established that IL-17 receptors can be found on many cell types
(Yao et al, 1997); our study has taken this further and shown that both IL-17RA and
IL-17RC are expressed on conjunctival tissues. This expression of IL-17RC in this
study was shown to be upregulated in chronic disorders. Further analysis provided
evidence that IL-17RA can be upregulated by pro-inflammatory cytokines and TLR
agonists, such as that seen in the inflammatory environment of chronic allergic
disorders. More interestingly we discovered that IL-17 ligation reduces the level of
IL-8 production by epithelial cells under specific conditions.
The evidence from the literature tells us that IL-17 receptor signalling drives the
production of pro-inflammatory cytokines; it was therefore not surprising that our
data suggests that TLR ligands as well as inflammatory cytokines - which can be
detected at the inflamed ocular surface – were shown to upregulate IL-17RA in our
model. Hence, IL-17R expression may be part of an important defence mechanism
against ocular infection, which may be essential to subjects that risk the development
of secondary infections during anti-inflammatory therapy. Conversely, the
expression of IL-17RC and IL-17RD was not affected by epithelial cell stimulation;
this may be due in part to the very high levels of expression of both these receptors
on unstimualted cells. Unlike IL-17RA and IL-17RC, IL-17RD is poorly understood
and therefore we are currently unable to draw any conclusions regarding its
expression on the cells or its role in epithelial cell responses.
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In studies investigating IL-17R signalling, mice deficient in IL-17R displayed
significantly reduced expression of IL-1α, IL-1β and IL-6 (Koenders et al, 2005) and
a decrease in neutrophil migration (Conti et al, 2009; Freitas et al, 2009). Our
hypothesis in this study was that IL-17RA blockade downregulates conjunctival
epithelial cell responses. We therefore investigated the contribution of IL-17RA in
epithelial responses by, firstly, stimulating conjunctival epithelial cells for 24 hours
to upregulate the receptor, blocking IL-17RA function and then determining
epithelial cell responses to IL-17A. Our initial observations demonstrated that IL-
17A ligation had no effect on CD54 expression as previously shown by our earlier
studies. During receptor blockade, the effect of IL-17A was reversed and the
expression of IL-17RA was comparable to the level found on unstimulated cells. In
relation to the effect of anti-IL-17RA treatment on receptor expression, treatment of
cells with control IgG lead to down-regulation of IL-17RA, probably due to receptor
internalisation. Unexpectedly we detected enhanced IL-17RA expression in response
to IL-17A in those cells pre-treated with TNF-α + IL-1β, which was unaffected by 
anti-IL-17RA, presumably due to the overriding effect with such a potent
stimulation. The anti-IL-17RA antibody did significantly reduce IL-17RA expression
in epithelial cells if they were pretreated with the poly I:C.
In contrast to our current understanding of a pro-inflammatory role for IL-17 in
upregulating IL-8, IL-17RA neutralisation on conjunctival epithelial cells increased
the levels of IL-8 when compared to controls, but only in those cells prestimulated
with PMA, IL-17A or poly I:C. This unexpected finding suggested that IL-17RA
plays a role in modulating IL-8 production. The mechanism for these actions remains
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unclear but a recent study focussing on the interaction of IL-17 with its receptors
revealed that IL-17A bound to both IL-17RA and IL-17RC with high affinity. In
conjunction, the affinity for IL-17RC was greatly increased after IL-17A was bound
by one IL-17RA molecule (Ely et al, 2009). Since we know that our epithelial cells
also express IL-17RC, it might explain the enhanced levels of IL-8 in response to IL-
17RA blocking, though this does not explain why a similar, if not increased
production of IL-8 was not seen in cells treated with control IgG.
In the last chapter we briefly discussed another member of the IL-17 family, IL-25,
which is thought to be involved in the initiation of Th2 immunity through the
induction of IL-5 and IL-13 (Fort et al, 2007). IL-25 has, however, been
demonstrated to be immunoregulatory for IL-8 responses (Xu et al, 2010), and for
pro-inflammatory cytokine production (Owyang et al, 2006; Kleinschek et al, 2007).
A recent study has shown that, in order for IL-25 to be activated, it must first be
captured by IL-17RB before binding to IL-17RA (Ely et al, 2009; Rickel et al,
2008). We found in our previous study that poly I:C treatment enhanced conjunctival
epithelial cell secretion of IL-25. The resulting IL-25 could have bound to IL-17RA
which would explain why an increase in IL-8 production was seen in those poly I:C
treated cells receiving anti-IL-17RA antibody since IL-25-mediated regulation of IL-
8 production would have been bypassed. Clearly our findings highlight IL-17RA as
being important for downregulating IL-8 production by PMA-, IL-17A- or poly I:C-
stimulated epithelial cells in response to IL-17A. Other groups have reported a
possible role for IL-17 in regulating immune responses. As well as initiating allergic
asthma, IL-17 was able to reduce pulmonary eosinophil recruitment and bronchial
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hyperreactivity in a mouse model (Schnyder-Candrian et al, 2006). In addition, Voo
et al observed CD4+ FOXP3+ cells that express the Th17 selective receptor, CCR6,
and produce IL-17 (Voo et al, 2009). These studies demonstrate the opposing roles
IL-17 may play in the pathogenesis of disease and controlling the immune response.
TGF-β1 secretion by unstimulated conjunctival epithelial cells was significantly 
downregulated in response to IL-17 in the presence of anti-IL-17RA antibody,
suggesting an important role for IL-17RA ligation in TGF-β1 production by 
epithelial cells. Whilst TGF-β is not necessary for Th17 differentiation in humans, in 
the context of our study, it may serve to play its role as an important anti-
inflammatory cytokine. It is interesting that this effect was only observed in
unstimulated cells, whereas the IL-8 modulation was only found on stimulated cells,
suggesting these two IL-17RA-dependent responses occur under different culture
conditions. The signalling events may provide an explanation for the opposing
effects following IL-17A ligation to IL-17RA on IL-8 and TGF-β observed in this 
study. Currently, IL-17RA signal transduction is poorly understood (Gaffen, 2009).
Studies have identified two possible signalling pathways that are involved in IL-17A-
IL-17R ligation. One of the pathways that have been described works through
ACT1/TRAF6/TAK1-dependent NF-κB activation (Huang et al, 2007). Normal IL-
17RA signalling requires the binding of ACT1 to TNFR-associated factor 6 (TRAF6)
leading to its related downstream molecule TGF-β-activated kinase 1 (TAK1) and 
subsequent NF-κB activation. In our study, IL-17RA blockade resulted in a decrease 
in TGF-β which may have resulted in a lack of TAK1 phosphorylation. Similarly, 
TRAF6 is also required for myeloid differentiation primary-response protein 88
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(MyD88) (Huang et al, 2007), one of the adaptor proteins involved in TLR
signalling. Pre-activation of the cells may have upregulated certain signalling
molecules and skewed responses towards the MyD88 pathway, which could have
resulted in IL-8 upregulation. Although we offer many suggestions as to the
mechanisms involved, the supernatants from the control treated cells were unable to
suppress lymphocyte proliferation below that of anti-IL-17RA treatment. This could
be due to the high levels of TGF-β that these conjunctival epithelial cells express 
constitutively, therefore abrogating any effect that IL-17 ligation may have had. Any
future studies will aim to investigate these IL-17R-mediated effects in more detail, in
particular the contribution of IL-17RC and the signalling molecules involved.
This study has highlighted a potential immunoregulatory role for IL-17 at the level of
its receptors. We have shown increased expression of IL-17RA localised to the
conjunctival epithelium, and our model has demonstrated that IL-17RA ligation leads
to a decrease in IL-8 and an increase in TGF-β1 secretion. Taken together, it is clear 
that the conjunctival epithelium possess an array of features that allow it to play an
active role in inflammation but more importantly it also displays anti-inflammatory
characteristics.
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Summary & conclusion
The epithelium can mediate inflammation through its ability to secrete various
cytokines and chemokines, thereby allowing the recruitment and activation of other
cell types as well as enhancing T helper cell responses (Swamy et al, 2010). With the
increasing literature directed towards inflammation, the epithelium is fast becoming a
focal point in allergy. The key observations of this study have highlighted increased
expression of the Th2 associated cytokines, IL-13 and TSLP as well as IL-17 in
chronic inflammation such as that seen in CAED. More interestingly we discovered
that under the influence of its receptor, IL-17 may downregulate inflammation under
certain circumstances. These results are the first of its kind to be demonstrated in
CAED and human conjunctival epithelial cells.
The increasing prevalence of allergy has in the past been attempted to be explained
in the context of T helper cell subsets, this concept has been referred to as the
‘hygiene hypothesis’ and it describes the events that are thought to contribute to
atopy. This idea was first proposed by the observations made by Strachan on hay
fever and the number of older children in the household, the author suggests that if
there are older siblings in the family, younger siblings have a decreased prevalence
of hay fever (Strachan, 1989). One theory for this phenomenon is that early
childhood infection via unhygienic contact with older siblings or acquired prenatally
by a mother infected by contact with her older children, may prevent the onset of
allegic diseases. The increased expression of atopic disease may therefore be as a
result of higher standards of personal hygiene thereby reducing the occurrence of
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cross infection (Strachan, 1989). In relation to T helper subsets, it has been argued
that bacterial and viral infections during early life direct the immune system towards
a Th1 phenotype and the production of IFN-γ, inhibiting Th2 responses. Further viral 
or bacterial infection and therefore Th1 activation may prevent the proliferation of
Th2 cells and thus the development of allegic disease (von Mutius, 2001). In keeping
with this theory, a more recent study has demonstrated that mouse models of allergic
airway disease, when infected by Helicobacter pylori, exhibit reduced airway
hyperresponsiveness as well as the lessening in inflammation and goblet cell
metaplasia which are characteristic of asthma. Within the BALF of these mice, IL-5
secretion and pulmonary infiltration of Th2 and Th17 cells was diminished. These
observations were found to be more strongly induced in infected neonates than adult
infected mice (Arnold et al, 2011). From both studies it can be thought that an
increase in allergy may ensue due to a reduction in microbial burden, leading to
diminshed Th1 activation and uncontrolled Th2 responses.
We have previously discussed the findings of recent years which have implicated
another T helper cell subset – Th17 in the pathogenesis of certain diseases; our
findings have also shown these cells to be present in CAED. As Th1 and Th2 cells
have been the focus of the hygiene hypothesis, it is likely that recent discoveries
concerning Th17 cells would require this idea to be revised. The question can be
asked as to where Th17 cells fit in regarding this hypothesis. Although differing in
their development and phenotypical characteristics, reports have suggested that there
are some shared similarities between Th1 and Th17 cells, mainly in their expression
of surface molecules (Nakae et al, 2007). This similarity may be important as some
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diseases that were once classified as being Th1 driven have been redefined and show
that Th17 cells may influence the pathology such as that seen in EAE. Adoptive
transfer experiments in these mice concluded that IL-17 producing T cells were more
efficient at inducing EAE than T cells producing IFN-γ alone (Langrish et al, 2005).
The ability of IL-23 to induce IL-17 expressing T cells can also be expanded to
include IFN-γ production and proliferation of T cells (Oppmann et al, 2000). More
interestingly, recent data has now shown that there are some cells which have the
ability to produce both IL-17 and IFN-γ, and Th17 cells can be converted to IFN-γ 
producing cells by IL-12 and IL-23, highlighting the plasticity of Th17 cells and the
parallels they share with Th1 cells (Lee et al, 2009). If we go back and put this in
context with the hygiene hypothesis, the proposed favouring of Th1 activation may
also include that of Th17 cells, perhaps even more so as they are involved in host
defence and their cytokine IL-17 is also produced by innate cells.
The role of Th17 cells and IL-17 in the immune response may be of great importance
when considering inflammatory disease, particularly in the lungs as demonstrated by
new studies. Secondary lymphoid organs create an environment that facilitates the
activation of T cells and B cells, allowing immune reactions to occur more efficiently
(Cupedo, 2011). Recently one group has defined a role for IL-17 in the development
of lymphoid tissues in the lung. These tissues that form in the lung are generated
ectopically and are known as inducible bronchus-associated lymphoid tissue
(iBALT) which occur after infection or inflammation and is more apparent in chronic
disease (Randall, 2010). Their development in LPS treated mouse neonate models
has now been associated with T cell ˗ IL-17 signalling; furthermore the chemokines 
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involved in conventional lymphoid organ formation, CXCL13 and CXCL19 are
thought to be induced by IL-17 (Rangel-Moreno et al, 2011). The formation of
lymphoid tissues due to exposure to microbes would therefore be important in
influencing the immune response.
It is unclear as to whether the hygiene hypothesis can be used at this juncture to
explain the increased frequency of allergy. Exposure to bacteria and viruses in
neonates or in early childhood and the resulting production of Th1 and Th17 cells
cannot justify a causal link to exaggerated Th2 responses. The actions of TSLP in the
induction of proallergic Th2 responses have already been proposed. Tanaka and
colleagues further show that the response to TSLP and poly I:C by dendritic cells
promotes the differentiation of Th17 cells and reduces IL-17 and IFN-γ double 
producing cells (Tanaka et al, 2008). Moreover, in lung tissues of a mouse model,
IL-17 was reported to be induced by allergen and was capable of reducing eosinophil
recruitment and Th2 cytokine production (Schnyder-Candrian et al, 2006). This
evidence casts more doubt onto the hygiene hypothesis as it fails to take into account
the regulatory role T helper cytokines play between the different subtypes and
suggests that there may be more of a balancing act between these cells and the
outcome of allergic disease.
As well as TSLP, other epithelial cell derived cytokines have now become the focus
of attention, such as IL-33. This new member of the IL-1 super family is also
produced by other cell types and can activate Th2 cells and mast cells leading to the
secretion of proinflammatory and Th2 cytokines (Schmitz et al, 2005). IL-33 has
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been implicated in allergic asthma with studies showing increased immunoreactivity
of epithelial IL-33 in patients with severe asthma (Préfontaine et al, 2010). This
cytokine also has the ability to stimulate innate cells such as basophils, to secrete Th2
cytokines and can work without the aid of T cells (Kondo et al, 2008). More recently
studies involving mouse models of airway hyper-reactivity (AHR) have revealed that
its induction can occur via IL-33 activation of an innate lymphoid cell type termed
‘natural helper cells’ (Chang et al, 2011). The authors demonstrate that AHR
development by H3N1 infection can induce IL-33 production which in turn activates
natural helper cells to produce IL-13 – more so than other cell types (Chang et al,
2011). This may have implications in CAED as one study has reported a possible
role for IL-33 in chronic allergic conjunctivitis (Matsuda et al, 2009) and our study
has shown non T cell expression of IL-13 in the conjunctival tissues, albeit the
expression of IL-13 could be because of its binding to other cells.
As new reports reveal the presence of certain cell types and cytokines in
inflammation and disease, it has become increasingly important to determine
effective therapies to overcome an over-active immune system. This may involve
targeting receptors on the cells that would block their activation or antibodies that
neutralise specific cytokines and chemokines. As this study has demonstrated the
presence of TSLP and IL-17 in CAED, they could be important targets in disease
control or prevention. To date a few groups have focussed their investigations on
blocking the TSLP receptor (TSLPR). One such group demonstrated an increase in
TSLP in asthmatic mice, following blockade with a TSLPR neutralising antibody led
to a decrease in eosinophils and lymphocytes as well as a reduction in IL-4 and IL-5.
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Whilst there was a decrease in Th2 cytokines, IFN-γ and IL-10 were increased (Shi 
et al, 2008). At the same time a study was published on the use of imidazoquinoline
compounds – imiquimod and its derivative R848 (ligands to TLR7 and TLR8) – to
suppress TSLP-DC mediated inflammatory Th2 cell responses. Treatment of human
DCs with TSLP and R848 significantly reduced levels of IL-4, IL-5, IL-13 and TNF-
α whilst increasing IL-10 and IFN-γ (Torii et al, 2008).
There are also endogenous mechanisms that have been proposed to serve a role in
inhibiting TLR-dependent inflammatory responses, one such example is SHP (small
heterodimer partner); an orphan member of the nuclear receptor superfamily, that
contributes to transcriptional regulation. A recent study has shown that LPS-
stimulated macrophages from SHP knockout mice have greater TNF, IL-1β and IL-6 
protein and mRNA expression than SHP+/+ mice (Yuk et al, 2011). This same study
demonstrated that the mechanisms involved were due to the inhibition of TLR
signalling pathways – both MyD88 dependent and independent (TRIF pathway) –
downstream of various ligands (Yuk et al, 2011). In context with inflammatory
diseases, this may be a potential therapeutic target. Certain agents, MSP
(macrophage stimulating protein), metformin and AICAR (5-aminoimidazole-4-
carboxamide-1-β-D-ribofuranoside) have already been found to induce the 
expression of SHP in hepatocytes (Chanda et al, 2009; Kim et al, 2008). MSP in
particular has shown that it can down-regulate TLR4 inflammatory responses in
SHP+/+ mice (Yuk et al, 2011).
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Like TSLP, the increasing literature on Th17 pathogenesis has led researchers to
investigate therapies aimed towards reducing IL-17 in order to ameliorate
inflammatory disease. So far certain drugs, namely Methotrexate and/or Etanercept
have been used to redress the balance of Th17 cells in RA patients (Li et al, 2011;
Lina et al, 2011). In other disease settings it may be useful to target the cytokines
that drive Th17 expansion such as IL-23. Previous work has described the protection
of mice from psoriasis after treatment with an anti-IL-12 mAb which reacts against
the IL-12 (p35/p40 (p70)) heterodimer, and a fully human anti-IL-12/23 antibody
called ABT-874 has been reported to reduce the psoriatic area by 75% (Hong et al,
1999; Kimball et al, 2008). As IL-23 consists of a p19/p40 chain it could be a target
for the amelioration of disease. The inhibition of IL-17 signalling through its receptor
may also be an effective method. As IL-17RC has a higher affinity for IL-17A, an
antibody directed towards this receptor could neutralise both IL-17A and IL-17F.
Investigators may also target IL-17A, but as this cytokine appears to have many
functions, blocking its total production may not be wise. As innate cells can also
produce IL-17, researchers should possibly concentrate on targeting the production
of IL-17 by Th17 cells therefore allowing innate IL-17 production to carry out its
role in host defence. Furthermore, it may also be possible to exploit the plasticity of
Th17 cells in order to convert them to regulatory T cells, thereby suppressing
inflammation. The most recent studies have shown that human myeloid derived
suppressor cells (CD14+HLA-DR-/low) when cultured with Th17 cells decreased the
frequency of IL-17 secreting CD4+ cells while increasing FoxP3+ IL-17-CD4+ cells
(Hoechst et al, 2011). Moreover, human Th17 cells generated from tumour-
Chapter 7 Conclusion
Page 153
infiltrating lymphocytes that had been expanded in the presence of OKT3 and
allogeneic PBMCs, decreased in number in contrast to increased percentages of IFN-
γ producing and FOXP3+ cells (Ye et al, 2011). The authors suggest that this may be
due to repeated TCR stimulation. More interestingly, not only do these cells have
potent suppressive ability but they do not convert back to Th17 cells even under
Th17 polarizing conditions (Ye et al, 2011).
Through our own work and other studies to date, new theories have come to light,
but yet many questions remain unanswered regarding the complexity of immune cell
interactions and the role of the cytokine microenvironment in the immune response.
When we consider the range of receptors expressed and the ability to produce
cytokines that can both initiate and regulate inflammation, we can say that the
epithelium is central to immunity with characteristics that bridge both the innate and
adaptive arms of the immune response.
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“Look at a stone cutter hammering away at his rock, perhaps a hundred times
without as much as a crack showing in it. Yet at the hundred-and-first blow it will
split in two, and I know it was not the last blow that did it, but all that had gone
before”. ~Jacob A. Riis
